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Abstract 
Chronic skin wounds are a significant health condition caused by a wide range of factors. In 
Australia, it is estimated that over 200,000 people each year suffer from a chronic skin 
wound condition costing up to $285 million annually in treatments. Currently, severe cases 
of chronic skin wounds are treated using skin grafts and tissue engineered skin constructs. 
These devices are expensive and are unable to prevent infections. Without proper 
monitoring and replacement, these grafts and constructs can act as reservoir for pathogens 
to proliferate protected from the patient’s immune system. Infected wounds are often 
polymicrobial and the microbes able to produce biofilm which acts as a barrier between the 
microbe and antibiotic molecules.  
Currently, research is focused on the development of synthetic scaffolds with antimicrobial 
capabilities. Scaffolds created by other researchers either focuses on biocompatibility and 
mimicking of the extracellular matrix or delivery of drugs in a sustained release. Rarely both 
are combined due to problems of maintaining sustained drug release lasting the entire 
wound healing period. A two-part device consisting of a biocompatible biodegradable 
scaffold and bioactive glass microspheres to act as a delivery vector for antibiotics has been 
proposed in this thesis. This thesis will explore the methods of producing bioactive glass 
microspheres of various forms, attachment of the microspheres to the scaffold in a non-
destructive method and the drug loading and release profile of the device when combined 
together. 
Results from this thesis show that wholly formed and hollow microspheres can be produced 
using a flame spray technique. Attachment of these microspheres to the scaffolds can be 
achieved by taking advantage of the low glass transition phase of the scaffold material while 
minimising scaffold damage. Microspheres attached using these methods are mechanically 
stable. Drug released from microspheres attached to the scaffold are significant but not 
sustained. In conclusion, a two-part wound healing device can be used to treat infected 
chronic wounds. 
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1 Introduction 
Chronic skin wounds are defined as skin wounds which do not heal in the normal manner or 
time due to complications. Chronic wounds are in a constant state of inflammation as the 
body attempts to recover [1–4]. During this period, there is a high risk of infection of the 
wound which are known to increase the severity of the wound and lead to other health 
issues [4–6]. In Australia, it is estimated that over 200,000 people each year suffer from a 
chronic skin wound condition [7]. This amounts up to $285 million annually in treatments [7].  
Currently, severe cases of chronic skin wounds are treated using skin grafts and tissue 
engineered skin constructs. These grafts are generally expensive costing up to $33/cm2 and 
often require multiple replacements to maintain the biological benefits [8]. In large chronic 
wound cases, there is also the issue of vascularisation of the graft. Poor vascularisation will 
lead to graft failure and tissue necrosis of the graft [9, 10]. Grafts are susceptible to 
infections by microorganisms, especially during the initial stage post implantation. The graft 
can act as a reservoir for infectious microorganisms to proliferate where they are protected 
from the body’s immune system due to poor vascularisation [11]. In addition, antibiotics 
administered intravenously are unable to penetrate deep within the graft if there is poor 
vascularisation [6, 12].  
In response to these issues facing biological grafts, research is focused on the development 
of synthetic scaffolds with antimicrobial capabilities [13]. Scaffolds created by other 
researches either focuses on biocompatibility and mimicking of the extracellular matrix or 
delivery of drugs in a sustained release. Rarely both are combined due to problems of 
maintaining sustained drug release lasting the entire wound healing period [14, 15].  
In this thesis, a two-part device consisting of a biocompatible biodegradable scaffold and 
bioactive glass microspheres to act as a delivery vector for antibiotics will be developed. 
Chapters within will explore methods of producing bioactive glass microspheres of various 
forms, attachment of the microspheres to the scaffold in a non-destructive method and the 
drug loading and release profile of the device when combined together. 
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2 Literature Review 
2.1 Anatomy and Physiology of the Skin 
The skin is the largest organ of the body acting as a multifunctional barrier between the 
internal components of the body and the external environment. It has an average surface 
area of 1.75m2 and weighs approximately 15% of the body mass [1, 16]. Average thickness of 
the skin lies between 0.5 – 5 mm depending on the skin location on the body [17, 18]. Skin 
thicknesses can also vary significantly between individuals, and the age of the individual [19, 
20]. It is typically thinner in infants and elderly persons [21]. Other features of the skin that 
may differ between individuals include skin colour, texture, thickness and appendages such 
as hair [20, 22, 23]. 
Compared to other organs of the body, the structure and physiological role of the skin may 
appear relatively simpler. Nevertheless, the skin is a complex structure consisting of many 
different types of specialized cells and tissue structures which serve the broad purpose of 
providing and maintaining a barrier to the external environment.  
2.1.1 Anatomy 
The skin can be classified into three distinct layers as seen in Figure 2-1. Going from external 
to internal, these layers are the epidermis, the dermis and the hypodermis or subcutaneous 
layer. 
 
Figure 2-1: Anatomy of the skin showing the main structures of the skin [1]. 
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2.1.1.1 The Epidermis 
The epidermis refers to the external layer of skin exposed to the environment. The layer is 
approximately 0.1 – 1.5mm thick depending on body location [1, 19]. The majority of cells in 
the epidermis are keratinocytes which make up to 90% of the epidermal cellular composition 
[21].  
Keratinocytes form a stratified squamous layer of cells which forms a watertight layer and 
prevents foreign objects from invading the body [1]. These cells are formed from an internal 
cell layer known as the basement membrane. As new cells form, older cells are pushed 
towards the surface of the skin. In the process, the cells differentiate and change 
morphology due to the internal cell production of keratin [20]. Keratinocytes eventually die 
and become a hydrophobic layer of cells which continuously slough of the skin [24]. It can 
take approximately 40 to 50 days for new keratinocytes to reach the surface and slough off 
depending on the thickness of the skin [25]. 
Other cells present include melanocytes, Langerhans cells and Merkel cells. Melanocytes are 
irregular-shaped cells which produce melanin, a group of pigments which gives colour to the 
skin and provides some protection against ultraviolet light [26]. Langerhans cells are a group 
of dendritic cells or antigen presenting cells (APCs) which function as part of the immune 
system gathering extracellular antigens [22, 27].  Langerhans cells are able to leave the skin 
and migrate to lymphatic nodes via the lymphatic vessels where they help initiate immune 
responses to the antigen [27]. Merkel cells are specialised epidermal cells which are 
associated with mechanoreceptors in the skin [19, 28].  
2.1.1.2  Dermis 
The dermis lies anatomically deep to the epidermis and superficial to the hypodermis [1, 17, 
20]. The cell population of this layer consists of fibroblasts, adipose cells and macrophages 
[1, 17, 20]. A key characteristic of the dermis is the fibrous network which consists mostly of 
two proteins that are secreted by fibroblasts; collagen and elastin [29]. Collagen provides 
mechanical strength while elastin provides the elasticity component of the skin.  In addition, 
there are reticular fibres and glycosaminoglycans in the fibrous network [30]. Also present in 
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the dermis are a number of other structures which include blood vessels, nerve endings and 
receptors, lymphatic vessels, sebaceous glands and hair follicles [1, 18].   
 The dermis can be divided into two layers; the papillary layer and the reticular layer. The 
papillary layer forms a junction with the epidermis and is characterised by appendages 
known as dermal papillae which extends into the epidermis. It consists of loose connective 
tissue and blood vessels which supply the epidermis with nutrients, remove waste products 
and aid in regulating body temperature [17]. The reticular layer lies beneath the papillary 
layer and forms a continuous layer with the underlying hypodermis. This layer is composed 
of dense irregular connective tissue which is able to resist stretching in many directions [19].  
2.1.1.3  Hypodermis 
The hypodermis is the most internal layer of the skin and is comprised of fibroblasts, adipose 
cells and macrophages in a loose connective tissue network comprising of collagen and 
elastin fibres [1]. The layer separates the dermis from the underlying structures of deep 
fascia, muscle and bone. It is mostly comprised of adipose tissue with approximately half of 
the body’s fat stored here [22]. The adipose tissues function as a source of energy, insulation 
and padding to absorb mechanical loads [1].  
2.1.2 Physiology 
Despite its relatively simplistic structure compared to other organs of the body, the skin is 
able to perform a number of important functions. These include: 
• Protection of our internal body from the physical, chemical and biological substances 
in the environment  
• The sensations of touch and thermal detection  
• The regulation of body temperature through the secretion of sweat and exposed 
surface areas  
• The synthesis of vitamin D  
• Water resistance to prevent essential nutrients being removed from the body.  
• Excretion of waste products such as salts and certain organic compounds. 
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• Detection and immunity to foreign pathogens. 
• Acting as a reservoir for up to 10% of the total blood flow in an adult which aids in 
temperature regulation and blood supply for active muscles during strenuous 
exercise [1, 20, 31]. 
Of particular interest are the skin’s defences to pathogenic microorganisms. This is important 
as infections in chronic wounds and skin grafts are common [32, 33]. 
2.1.2.1  Defence mechanisms of the skin 
The skin has a number of mechanisms to prevent infection and pathogenesis of 
microorganisms [34–37]. These include: 
• Chemical environment of the skin 
• Desquamation of the skin 
• Endogenous microflora of the skin 
• Innate immune cells 
Of particular interest is the role of endogenous microflora and the innate immune system. 
These aspects of the skins defence mechanisms have a significant role in wound healing and 
infection control. For chronic wounds, microbial flora and innate immune cells are often 
critical factors which have a role in prolonging wound healing.  
2.1.2.1.1 Endogenous microflora of the skin 
Despite the harsh chemical and physical environment of the skin, there are certain types of 
microorganisms which are found naturally on our skin. These microorganisms, termed 
endogenous microflora, are generally non-pathogenic whilst residing on the skin. The 
microflora of the skin helps prevent attachment and colonisation of pathogenic 
microorganisms though competition of colonisation sites limiting regions where foreign 
microorganisms can attach and limited nutrients which are necessary for proliferation. 
Common microorganism species which are native to the skin include Staphylococcus, 
Micrococcus, Corynebacterium, Propionibacterium, Malassezi, Brevibacterium, Acinetobacter 
and Dermabacter [16, 38, 39]. Whilst these microorganisms pose no harm residing on the 
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skin surface, they can become pathogenic and pose serious health risks if they infect and 
colonise an open wound [5, 16].  
2.1.2.1.2 Underlying immune cells 
In the event that the skin barrier is disrupted and broken, there are a number of immune 
functions which are capable of suppressing and removing infectious microorganisms. As 
mentioned before in section 2.1.1.1  The Epidermis, one of the key immune cells in the 
epidermis are Langerhans cells, a type of APC. Langerhans cells are able to detect and 
phagocytose exogenous antigens, process the antigens and migrate to lymph nodes where 
they present the antigens to CD4 T helper cells. CD4 T helper cells respond by initiating the 
appropriate immune response whether it is activation of CD8 cytotoxic cells or activation of 
B cells to produce immunoglobulins [40–42].  
In addition, neutrophils also play a large role in the immunity of the skin, particularly where 
there has been a physical breach of the skin resulting from physical trauma and burns. 
Neutrophils are able to reach the wound site through the blood vessels and are attracted by 
chemoattractants released by cells at the wound site. At the wound site, they are involved in 
the eradication of bacteria through phagocytosis and are able to activate and attract more 
immune cells through the secretion of cytokines and chemoattractants [41–44]. 
2.2 Physiology of Wound Healing 
Wound healing is a complex process in which multiple cells and extracellular pathways are 
activated in a tightly regulated and coordinated manner. Factors which cause skin wounds 
can be defined in three broad categories [1].  
• Physical wounds caused by mechanical forces or physical trauma to the skin. 
• Chemical wounds where corrosive reactions occurring at the skin damage 
surrounding cells. 
• Biological wounds whereby cells of the skin die due to lack of nutrients or infection. 
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2.2.1 Acute Wound Healing 
There are a number of methods which can be used to describe acute wound healing. The 
process of wound healing can be classified into four main stages [1, 40, 41, 43, 45]. These 
stages in chronological order are: 
• Haemostasis 
• Inflammation 
• Proliferation 
• Maturation and Remodelling 
These stages do not operate in isolation as there is considerable overlap between adjacent 
stages. Relationships between the wound healing stages as depicted in Figure 2-2 and 
described in detail in the following sections.  
 
Figure 2-2: Phases of wound healing and associated events [43]. 
2.2.1.1 Haemostasis 
At the time of injury where the skin has been breached and underlying blood vessels have 
been damaged, the body immediately responds to prevent exsanguination and promote 
haemostasis. Damaged arterial vessels rapidly constrict leading to reduced blood flow [41]. 
This in turn leads to tissue hypoxia and acidosis. While in this state, there is an increased 
production of nitric oxide, adenosine and other vasoactive metabolites which promote 
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vasodilation and arterial relaxation [41]. Injured skin cells release clotting factors which 
activate the extrinsic clotting cascade[5]. In addition, platelets are recruited to the wound 
site by cytokines such as serotonin and platelet factors.  
A fibrin clot forms over the injury site preventing the influx of microorganisms [41]. The clot, 
made of platelets, fibrin and fibronectin, also plays a role in wound healing acting as a 
scaffold matrix that guides and supports the infiltration of fibroblasts and keratinocytes [41]. 
The fibronectin protein acts as a chemoattractants for wound repair cells, acts as a template 
for collagen fibre deposition, and participates in wound debridement by degrading 
extracellular matrix (ECM) debris and activating phagocytic characteristics in macrophages 
[46]. When the clot is no longer useful, it is degraded by the enzyme plasmin which breaks 
down the fibrin matrix [47].  
Cytokines play an important role in wound healing. Cytokines released during the process are 
highly potent and specific in their action in the microenvironment of the wound site. One 
group of cytokines, platelet-mediated growth factors, are responsible for fibroblast and 
keratinocyte migration, synthesis of collagen and other extracellular matrix products, 
regulation of cell movement, direction of new capillary growth and synthesis of enzymes 
used in remodelling newly formed connective tissue [48]. 
2.2.1.2 Inflammatory response 
The inflammatory response begins within minutes of the initial damage and is characterized 
by the influx and actions of many types of leukocytes (colloquially known as white blood 
cells) at the wound site to arrest any infections and remove wound debris and dead tissue 
[40, 41, 43]. 
One of the most prominent leukocytes involved in this phase are neutrophils. Neutrophils 
are the most abundant leukocyte in the body accounting for 50-70% of all leukocytes in the 
body. These cells are recruited from blood vessels near the wound site through the action of 
chemokines secreted by cells in trauma near the wound site [49]. Once present at the wound 
site, the primary function of neutrophils is to phagocytose bacteria cells and break them 
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down through to release of reactive oxygen species and hydrolytic enzymes. Neutrophils will 
continue to migrate to the wound site until the infection has been arrested. In addition, they 
are also involved in the breakdown of extracellular matrix and secretion of cytokines in 
preparation for proliferation and maturation stages. In time, neutrophils are removed by 
either apoptosis or macrophage phagocytosis [49–51].  
Macrophages are another important type of leukocyte. Macrophages are the derivation of 
monocyte cells which had been recruited from the blood and matured upon receiving of 
appropriate cytokine stimulus. Macrophages remove wound debris and bacteria much like 
neutrophils. In addition, macrophages secrete nitric oxides and cytokines to help regulate 
wound repair [52]. They also produce a key type of enzyme called matrix metalloproteinases 
or metalloproteases (MMPs). One such type, collagenase, is required for the degradation of 
the extracellular matrix in preparation for new matrix deposition [53].  
Some other key cells important to this phase are T lymphocytes, mast cells and dendritic cells 
[40–42]. These cells function as a component of the immune response to foreign bodies.  
2.2.1.3 Proliferation 
Proliferation is characterized by the development of new skin over the wound site and the 
restoration of vascular integrity to the region. The tensile strength of the wounded area 
begins to redevelop [1]. The key cells during this process are fibroblasts and keratinocytes. 
There are three key events which occur during proliferation: reepithelialization, angiogenesis 
and granulation. 
2.2.1.3.1 Reepithelialization 
Reepithelialization is the process where keratinocyte cells reform skin over the wound re-
establishing an external barrier that minimizes fluid loss and pathogen invasion [41]. 
Keratinocytes are stimulated by locally released growth factors and begin to rapidly 
proliferate and migrate across the wound bed within 12 to 24 hours of injury. Migration of 
keratinocytes relies on a number of factors. It requires a fluid environment and involves a 
series of complex steps controlled by chemokines and growth factors [31, 40, 41].  
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Figure 2-3: Diagram of migration of epidermal cells in (a) moist environment and (B) dry environment. Bottom diagram 
shows epidermal cell migration via cell proliferation and leapfrogging [41]. 
As seen in Figure 2-3, newly formed keratinocytes enter the moist fluid environment by 
detaching themselves from neighbouring keratinocytes and the basement membrane. The 
migrating keratinocyte elongates itself in the direction of the required growth. The leading 
edge of the elongated cell attaches to a new spot on the wound bed and the cell contracts, 
pulling itself across the wound. When migrating cells from opposite sides of the wound touch 
each other, the migration process ceases in a process known as contact inhibition. Another 
process used in reepithelialization is leapfrogging. As shown in Figure 2-3, leapfrogging is the 
process where a single cell moves only 2 or 3 cell lengths before stopping and allowing 
following cells to climb over [41].  
In addition, keratinocytes also play a role in reshaping the extracellular matrix through the 
degradation of supporting structures which are replaced by temporary anchors during 
keratinocyte migration. Once migration is complete, the keratinocytes stabilize themselves 
by forming strong attachments to neighbouring cells [54]. 
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2.2.1.3.2 Angiogenesis 
Angiogenesis (also known as neovascularization) is the process of restoring a vascular 
network to the repairing wound site [41, 55]. It is a critical component of wound healing as 
newly formed blood vessels provide a steady supply of nutrients and oxygen to the 
reforming skin. Angiogenesis is stimulated by growth factors and tissue hypoxia [56, 57].  
Before new blood vessels can be formed, there are a number of events which occur. Firstly, a 
hypoxic gradient forms between damaged tissue and well vascularized tissue. This is 
compounded when a fibrin clot forms to act as a temporary barrier to the environment.  
Once the clot is formed and the wound is sealed, angiogenesis can proceed. The hypoxic 
environment stimulates macrophages to produce angiogenic growth factors. A number of 
other growth factors secreted by platelets, fibroblasts and endothelial cells are also released. 
New blood vessel formation begins from intact blood vessels in the underlying dermis. New 
capillary buds form capillary loops which slowly extend into the wound environment [55, 57, 
58].  
2.2.1.3.3 Granulation 
Granulation refers to the development of a transitional substance which replaces the 
fibrin/fibronectin matrix known as granulation tissue. The tissue is metabolically active, 
supports proliferation and is highly vascular [1, 40, 41].  
Fibroblasts are the prominent cell type found in granulation tissue [29]. These cells produce 
collagen and numerous other proteins which build an ECM. In addition, the influx of 
fibroblasts helps degrade the provisional matrix and replace it with a new matrix rich in 
hyaluronan, fibronectin and other compounds. The new extracellular matrix allows for cell 
migration and organization [41]. The structure and composition of the granulation tissue 
undergoes constant remodelling until the skin tissue matures [40].  
2.2.1.4 Maturation and remodelling 
The last stage of wound healing involves processes involved in restoring the strength of the 
skin tissue. Granulation tissue matures into connective tissue. The key cells involves in this 
stage are macrophages and fibroblasts. The extracellular matrix reshapes through the cross-
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linking collagens, cell maturation and cell apoptosis. Collagen synthesis peaks around 5 days 
after injury and may last for months afterwards [45].  
Although the wounded skin region recovers some strength, it never achieves more than 80% 
of the pre-injury strength [41]. This ends the wound healing process for the skin under 
normal conditions. 
2.2.2 Chronic Wounds 
There are a number of varying criteria which can be used to describe chronic wounds. 
Chronic wounds are generally defined as wounds which do not heal in a normal and timely 
manner [1–4]. The normal wound healing process is interrupted and the wound enters a 
state of pathologic inflammation. This results in a delayed, incomplete wound healing 
scenario with poor anatomical and functional outcomes [46, 59].  
There are a number of factors which can lead to a chronic wound state. As listed in Table 2-1, 
these factors can generally be split into two categories. Local factors generally describe 
factors which directly influence the characteristics of the wound itself while systemic factors  
refer to the overall health and condition of the individual and his/her ability to heal [60]. It is 
important to note that many of these factors are related [60]. 
Table 2-1: Factors contributing to chronic wounds[1, 60] 
Local Factors Systemic Factors 
Infection Age and Gender 
Oxygenation Poor nutrition 
Foreign Body Underlying Chronic Disease 
Venous insufficiency Medication 
Necrotic Tissue Compromised Perfusion 
Local Pressure/shear and friction Alcohol and Smoking 
 Obesity 
 Ischemia 
 Immunodeficiency 
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There are a number of differences between acute and chronic wound states. In the broadest 
sense, cellular and molecular abnormalities in the chronic wound prevent acute wound 
healing processes from occurring. In the majority of chronic wounds, there is excessive 
recruitment of inflammatory cells, such as neutrophils, to the wound site. This is most often 
due to the presence of an infection [4, 5]. Excessive recruitment of inflammatory cells which 
fail to harness the infection can also impair wound healing through the production of various 
reactive oxygen species which damage extracellular matrix and cell membranes [61]. In 
addition, they can also increase the production of proteases and MMPs. Overproduction of 
proteases and MMPs can accelerate extracellular matrix degradation and inactivate 
components of the extracellular matrix and growth factors leading to an impaired wound 
healing process. This process explains why there is a limited quantity and bioavailability of 
growth factors in chronic wounds [62].  
2.2.2.1 Epidemiology 
Chronic wounds are a global issue and are thought to affect a significant portion of the 
population in developed countries [63]. For the elderly, defined as persons aged over 65 
years, the rate increases due to poorer health and healing outcomes [64].Between 1998 and 
2008, there was a rise in the number of patients admitted with a skin and soft tissue 
infection in Australia [65]. 
Chronic wounds are a significant burden to the individual and the public. Studies indicate 
that the cost of treatment and care for chronic wounds is around 3% of the total healthcare 
expenditure in developed countries. For Australia, this equates to approximately $2.6 billion 
in direct healthcare costs [66]. It is estimated that the cost of treating a chronic wound can 
reach up to $27,493 per wound [67]. The primary factor for the high cost arises from the 
prolonged length of time required for the wound to heal. Reported healing times for chronic 
wounds indicate that 69% heal in 12 weeks, 83% heal within 24 weeks and 17% remain 
unhealed after 52 weeks [67]. Other factors include treatment options and infrastructure 
costs [68].  
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Complications from chronic wounds are exacerbated in rural areas where there is a lower 
quality of healthcare due to less infrastructure and medical staff [69]. In addition, there is a 
higher incidence of chronic diseases in rural regions which can lead to the formation of 
chronic wounds [69, 70]. In particular, diabetes mellitus can lead to diabetic foot ulcers, a 
condition that affects 12-25% of all diabetic patients [71].  
Rural regions in Australia are significantly disadvantaged in healthcare compared to urban 
populations. This is due to numerous factors, in particular the lack of medical professionals 
and staff, inadequate infrastructure to service a sparsely populated region, lower healthcare 
expenditure for rural regions, lower education outcomes and income disparities [66, 69, 70, 
72].  
2.2.2.2 Infection 
One of the major complications associated with chronic wounds is infections. Infections of 
chronic wounds are the result of pathogenic organisms reaching a population threshold or 
producing toxins which overwhelm the patient’s immune system. A number of articles have 
defined infection of wounds as the presence of more than 105 organisms per gram of tissue 
or the presence of beta-haemolytic streptococci [4, 16, 73]. This definition however does not 
take into account other factors such as chronic illnesses and immunocompromisation.  
An infection is enough in itself to cause a wound to enter a chronic state. Pathogens such as 
bacteria, fungi and viruses have a number of virulence factors which help it colonise the 
wound. Some of the main factors include adhesion, colonisation, invasion, immune response 
inhibitors and toxins. Briefly summarising each point, adhesion refers to the aspect of a 
pathogen to attach itself to a surface which is a prerequisite for proliferation. Colonisation 
refers to the production of special enzymes or proteins which allow the pathogen to survive 
in particular areas of the body. Invasion describes the ability to produce enzymes to 
breakdown tissue or cell membranes allowing penetration. Immune response inhibitors are a 
variety of strategies a pathogen can use to evade or inhibit the host’s immune system. Finally 
toxins produced by pathogens can cause poisoning and cause tissue damage [74].  
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Another issue regarding infected chronic wounds is that the majority of chronic wounds are 
colonised by more than one type of microorganisms. A study by Hansson et al on leg and 
foot ulcer found that in 86% of wounds with no clinical sign of infection there was more than 
one type of bacterial species present [39]. Fungal pathogens are also present in some chronic 
wounds which can complicate treatment since antibiotics do not treat fungal infections [39, 
75].  
Table 2-2: Frequency of common microorganisms found in chronic wounds.  
Study Hansson et al (1995) 
[39] 
Gjodsbol et al 
(2006) [76] 
Davies et al (2007) 
[77] 
Number of patients 
involved 
58 43 66 
Test site Venous leg ulcers Venous leg ulcers Venous leg ulcers 
Microorganism Frequency (%) 
Staphylococcus aureus 88 93.5 71.2 
Pseudomonas aeruginosa  52.2 71.2 
Coagulase-negative 
Staphylococcus species 
- 45.7 62.1 
Enterococcus species 74 71.7 - 
Escherichia coli - 32.6 - 
Enterobacter species 29 - - 
Enterobacteriaceae and 
nonfermentive gram-
negative bacilli 
- 37 - 
Corynebacterium species - 30.4 - 
Bacillus species - 4.3 - 
Peptostretococcus species 29 - - 
Other anaerobes - 39.1 - 
Fungi 11 - 12.1 
 
A list of common microorganisms found in chronic wounds is presented in Table 2-2. 
Staphylococcus aureas is the most common bacteria found in wounds. This is primarily due 
to the fact that is it is found on the skin of around 35-60% of the human population allowing 
it to access the wound site with relative ease [78]. In addition, Staphylococcus aureus is also 
capable of producing a wide range of enterotoxins and cytotoxins which can overwhelm the 
patient’s immune system [16].  
16 
 
2.2.2.2.1 Biofilm 
Biofilms are a community of bacteria which have formed an attachment to a surface and 
produce an extracellular polysaccharides matrix [79–81]. The extracellular polysaccharide 
matrix covers the bacterial community and helps protect the microorganisms from the host 
immune defence and antibiotics. Protection from the hosts immune system is conferred by 
masking the surface markers of the bacteria from immune cells whilst protection from 
antibiotics is thought to be due to interfering with antibiotic diffusion into bacterial cells or 
by direct binding of antibiotics to the extracellular polysaccharide matrix[82]. It is estimated 
that the presence of biofilm reduces the effectiveness of antibiotic treatment by as much as 
1000 fold [83].  
Biofilms can be created by a number of pathogenic organisms include common species such 
as Staphylococcus aureus [84, 85]. Up to 80% of human infections are estimated to involve 
pathogenic biofilms [86]. In addition, most biofilms consist of multiple species of bacteria 
[82]. It is estimated that volume of biofilms consist of 80-85% extracellular polysaccharide 
matrix and only 10-15% cells [87]. 
2.2.2.2.2 Antibiotic Resistance 
One of the major emerging concerns of infections is the rise of antibiotic resistance in 
pathogens. Patients with chronic wounds are considered to be a high-risk group for the 
acquisition, carriage and dissemination of antibiotic resistant pathogens. Also, due to the 
polymicrobial nature of chronic wounds as mentioned in section 2.2.2.2 Infection, there is a 
higher chance of genetic exchange between bacteria which could lead to an increase of 
antibiotic resistance of multiple strains. The presence of antibiotic resistant pathogens in 
chronic wounds can significantly complicate treatment. Compared to non-resistant pathogen 
strains, the cost of treating antibiotic resistant pathogens can be between 1.3 to 2 fold 
higher [88].  
One of the most well-known antibiotic resistant bacteria is methicillin resistant 
Staphylococcus aureus (MRSA). In a study by Colsky et al [89] on hospitalised patients with 
leg ulcers, half of all the Staphylococcus aureus isolates found were methicillin resistant and 
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more than a third of Pseudomonas aeruginosa isolates were resistant to ciprofloxacin. MRSA 
infections are generally nosocomial meaning that they are most commonly acquired in a 
hospital setting. However, there has been a steady rise of MRSA infections picked up from 
the community leading to increased strain on treatment methods [90].  
Due to the rise of antibiotic resistance, there are many issues which need to be addressed 
regarding antibiotic loaded biomaterials. Devices which use antibiotics as a form of 
sterilisation or prophylactic inhibitory mechanism need to be carefully evaluated. The risks of 
antibiotics used in a preventative manner has been well documented, particularly in the case 
where antibiotics were added to animal feed [91]. For bioengineering, there is a need for 
strict guidelines and further clinical proof of the efficacy of antibiotic releasing devices, 
particularly if the device is designed as a first-line treatment for infections [92]. 
2.3 Overview of Treatment Methods for Chronic Wounds 
Wound dressings have a long history dating back to the ancient Egyptians around 3000-2500 
BC. Since then, wound dressings have changed significantly as more knowledge of the wound 
is discovered. There is now a large range of wound management products for use in different 
scenarios.  
When designing a wound dressing product, some desirable characteristics include: 
• Maintaining a warm moist environment 
• Protection from microbial infection and foreign material 
• Easy to apply 
• Comfortable to wear 
• Ease of removal 
• Minimisation of frequent dressing changes [93, 94] 
2.3.1 Traditional Wound Care 
Traditional wound care is primarily aimed at maintaining an ideal environment that allows 
natural wound healing events to occur without disruption. These dressings typically include 
cotton, wool, natural or synthetic bandages and gauzes. These dressings are typically used in 
18 
 
non-chronic wound cases where the wound is clean and dry or as a secondary dressing to 
absorb exudates and protect the wound [95]. 
Gauze dressings can provide some protection against bacterial invasion [96]. However, this 
protection is lost when the gauze becomes moistened from wound exudate or external 
fluids. In addition, gauzes become adhered to the wound over a period of time and are 
painful to remove. Gauze dressings also do not prevent moisture loss by evaporation leading 
to dehydration of the wound [95]. 
Another traditional technique commonly associated with wound care is debridement. 
Necrotic tissue cannot be revived and functions as a source of nutrients for pathogens. 
Necrotic tissue also encourages the overproduction of degradation enzymes which has 
negative impacts on wound healing. Surgical debridement can include cleaning the wound 
with saline or dilute antiseptic solution, using a curette to scape biofilms and, for extreme 
cases, surgical removal of dead tissue [97].  
Traditional wound products are generally not used in chronic wound cases and burns. They 
have been replaced by more recent and advanced dressings which are more suited to treat 
the complex issues of chronic wounds.  
2.3.2 Modern Wound Care 
Modern wound dressings refer to a large range of products developed to retain moisture and 
create the ideal wound healing environment. They are generally made from materials 
designed to provide or maintain moisture in the wound. 
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Table 2-3: List and descriptions of some products used in the treatment of wounds [93, 94, 98, 99]. 
Category Type Description Examples 
Dressings 
Low adherent 
dressings 
• Dressing with low 
adherence to the wound 
rather than non-adherent. 
• Typically used in 
conjunction with a 
secondary dressing 
• Unable to absorb exudate 
• MelolinTM 
• N-A UltraTM 
• ReleaseTM 
• TelfaTM 
• TricotexTM 
Semipermeable 
films 
• Allows transmission of air 
and water vapour whilst 
being impermeable to 
fluids and bacteria. 
• Flexibility allows use in 
difficult anatomical sites 
• Unable to handle large 
amounts of exudate 
• BioclusiveTM 
• MefilmTM 
• TegadermTM 
• OpSite FlexigridTM 
• OpSite PlusTM 
Hydrocolloids 
• Interactive dressing made 
of hydrocolloid base made 
from cellulose, gelatin or 
pectins with a 
polyurethane or foam 
backing 
• Forms a gel that promotes 
a moist wound 
environment 
• No secondary dressing 
required 
• Comfeel PlusTM 
• Cutinova HydroTM 
• GranuflexTM 
• TegasorbTM 
• AlioneTM 
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Hydrogels 
• Consists of insoluble 
polymer matrix with up to 
96% water content 
• Able to absorb exudate or 
hydrate dry wounds 
• Requires secondary 
dressings 
• GranugeTMl 
• Intrasite GelTM 
• Nu-GelTM 
• SterigelTM 
• AquaformTM 
• PurilonTM 
Alginates 
• Dressings which contain 
calcium or sodium alginate 
• Interacts with the wound 
to reshape and absorb 
exudate 
• Typically used on high 
exuding wounds 
• AlgisiteTM 
• AlgosterilTM 
• CurasorbTM 
• KaltostatTM 
• SorbalgornTM 
• SorbsanTM 
• TegagenTM 
Foam 
• Typically made from 
polyurethane or silicone 
foam 
• Transmit water vapour and 
oxygen and provides 
thermal insulation 
• Contains exudate 
• AllevynTM 
• BiatainTM 
• Cutinova HydroTM 
• LyofoamTM 
• TielleTM 
Antimicrobial 
• Generally refers to 
dressings with an 
antimicrobial compound 
• Used to treat and prevent 
further infections 
• Silver 
• Iodine 
• Copper 
• Metronidazole gel 
• Chlorhexidine 
• Hydrogen 
Peroxide 
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Antibiotics 
Topical 
• Typically administered as a 
cream, gel or ointment. 
• Generally not used due to 
poor penetration through 
tissue to infected site 
• Gentamicin 
• Metranidazole 
• Neomycin sulfate 
• Nitrofurazone 
• Bacitracin 
• Fusidic acid 
Systemic 
• Typically used to treat 
infected wounds 
• Requires administration 
via intravenous catheter 
• Penicillins 
• Cephalosporins 
• Aminoglycosides 
• Quinolones 
• Clindamycin 
• Metronidazole 
• Trimethoprim 
Other Honey 
• Used since ancient times in 
wound care 
• Has a number of useful 
wound healing properties 
• Insufficient studies to 
conclude effectiveness. 
• MedihoneyTM 
 
As depicted in Table 2-3, there are a number of product categories for modern wound 
dressings. They are typically used in conjunction with a secondary dressing to maintain their 
position and provide a protective barrier. As mentioned before, these modern wound 
dressings are primarily focused on maintaining wound moisture. In addition, gel-type 
dressings (hydrocolloids, alginates and hydrogels) are able to absorb wound exudate which 
can help maintain moisture and reduce wound pressure.  
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To maintain moisture levels in the wound, the majority of modern wound dressings are 
occlusive in nature. Occlusive dressings limit the transmission of fluids, water vapour and 
gases from the wound bed to the environment. A moisture vapour transmission rate of less 
than 35g of water vapour per square meter of dressing per hour is generally considered to be 
able to maintain moisture in the wound [94]. A moist wound environment also helps 
maintain a mildly acidic pH and relatively low oxygen tension creating an optimal condition 
for fibroblast proliferation and granulation tissue formation [94]. In addition, moisture helps 
prevent wound desiccation and facilitates epidermal migration, angiogenesis and connective 
tissue synthesis [100]. Occlusive dressings are also capable of limiting the pain of partial-
thickness wounds to a much greater degree than non-occlusive dressings [101].   
Another feature of modern wound care is the use of antimicrobial and antibiotic compounds. 
Antimicrobials refer to a group of chemical agents that can be used against microbes such as 
bacteria, fungi, viruses and parasites. Antibiotics refer to a subset of antimicrobials which 
have inhibitory or lethal effect on bacteria.  
2.3.2.1 Antimicrobials 
Antimicrobial compounds are being increasingly used in wound healing products particularly 
as an anti-infection mechanism. In Table 2-3, a number of antimicrobial substances were 
listed. Of particular interest are the use of silver and iodine in wound management.  
2.3.2.1.1 Silver 
Silver has been used for medicinal purposes and water purification since ancient Greece. It 
has broad antimicrobial properties, particularly against MRSA and vancomycin-resistant 
enterococci (VRE), as well as moderate anti-inflammatory properties. Silver needs to be 
presented in an ionic or nanocrystalline form to be antimicrobial [94, 102]. It also requires 
fluid within the wound bed for it to access all areas of the wounds [102]. Silver has several 
mechanisms of antimicrobial action. These include blocking nutrient transport through 
bacterial cell walls, denaturing proteins involved in microbial respiration and inactivation of 
protein translation and replication of DNA [94]. 
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Silver is known to be cytotoxic as it cannot differentiate between healthy cells and 
pathogenic bacteria. A study by Poon found that 0.5% silver nitrate solution, first used in 
1965 on extensive burns, is cytotoxic to keratinocytes and fibroblasts [103]. However, silver 
toxicity is less prominent in a clinical setting where tissue cells are arranged in a complex 
manner. Studies have found silver to have toxic effects in acute donor site wounds reducing 
healing rates [104]. However, in chronic wound cases, the benefits may outweigh the risks, 
especially in high risk cases where antimicrobial activity must be maintained [105]. 
2.3.2.1.2 Iodine 
Iodine is a broad-spectrum antiseptic commonly used to disinfect skin or clean grossly 
infected wounds. It is typically used in alcohol solution at 1% to 10% concentration. 
Povidone-iodine is a common antibacterial formulation and is available in solution, cream, 
ointments and scrub. One of the major advantages of povidone-iodine is the seemingly zero 
microbial resistance to the compound [106]. Another iodine compound is cadexomer iodine 
in which iodine is contained in spherical hydrophilic beads of cadexomer starch. Cadexomer 
iodine is able to absorb wound exudate and release iodine into the wound bed [93].  
There are a number of conflicting studies which question the effect of iodine in wounds. 
Povidone iodine is cytotoxic to fibroblasts and can interfere with epithelisation. However, 
the exact concentration varies between studies [93, 107].  
2.3.2.2 Antibiotics 
Antibiotics are the primary choice when dealing with infections. Approximately a quarter of 
all patients with chronic wounds are receiving antibiotics at any given time and 60% of those 
have received systemic antibiotics within the previous 6 months [107]. Patients receiving 
antibiotic treatment are generally given broad spectrum antibiotics due to the polymicrobial 
nature of infected wounds and lack of identification of the bacteria initially [108]. 
Application of antibiotics can be either topical or systemic. Generally for infected wounds, 
antibiotics are administered systemically as topical applications may not penetrate the tissue 
to reach deep infections. In addition, topical antibiotics side effects include host 
sensitisation, contact dermatitis and promotion of antimicrobial resistance [107]. It should 
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also be noted that systemic antibiotics should not be used in topical application products due 
to the risks of negative side effects and promotion of antibiotic resistance [93]. Systemic 
antibiotics are able to treat infections which are accessible to blood vessels. The use of 
systemic antibiotics include the risk of secondary infection sites at the cannula insertion, and 
liver and renal complications [6, 12, 108].   
Use of antibiotics as a prophylactic/prevention mechanism is under increasing scrutinisation 
due to the rise of antibiotic resistant organisms. As mentioned in section 2.2.2.2.2 Antibiotic 
Resistance, there is a need to develop strict guidelines into the proper usage of antibiotics in 
order to reduce the risk and prevalence of antibiotic resistant microorganisms.  
2.3.3 Tissue Engineered Skin Constructs 
Tissue engineered skin constructs refer to a range of products which contain a biologically 
derived component. These skin constructs have a long history with developing tissue 
engineering technology which has resulted in a number of commercial. Tissue engineered 
constructs are generally used in severe cases of burns, chronic wound developments and 
where large areas of skin need replacement and no suitable donor site can be identified. The 
key concept behind tissue engineered skin construct which differentiates them from 
traditional and modern wound care products is the ability to encourage regrowth of skin by 
filling wound defects, and delivering and activating growth factors and other cytokines that 
promote healing [8, 109, 110].   
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Table 2-4: List of tissue engineered skin constructs. Table adapted from Böttcher-Haberzeth (2009) [8]. 
 Commercial Product Company Layers 
Cellular 
epidermal 
replacement 
Epicel ® Genzyme Corp. Cultured epidermal 
autograft 
Epidex™ Euroderm GmbH Cultured epidermal 
autograft 
ReCell® Clinical Cell Culture 
(C3), Ltd. 
Autologous epidermal 
cell suspension 
Engineered 
dermal 
substitute 
Alloderm® LifeCell Corp. Acellular donated 
allograft human 
dermis 
Integra® Integra LifeSciences 
Corp. 
Thin polysiloxane 
(silicone) layer; cross-
linked bovine tendon 
Engineered 
dermo-
epidermal 
substitutes 
Aplifgraf® Organogenesis Inc. Human allogenic 
neonatal 
keratinocytes; bovine 
collagen type 1 
containing human 
allogenic neonatal 
fibroblasts 
OrCel® Forticell Bioscience, Inc Human allogenic 
neonatal keratinocytes 
on gel-coated non-
porous side of sponge 
containing human 
allogenic neonatal 
fibroblasts 
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Tissue engineered skin constructs can generally be sorted into three categories based on 
what layers of the skin they are designed to replace as seen in 
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Table 2-4. They include cellular epidermal replacements, engineered dermal substitutes and 
engineered dermo-epidermal substitutes. Cellular epidermal replacements generally consist 
of keratinocyte sheets cultured on a membrane. The keratinocyte sheet is applied to the 
patient’s dermis using a synthetic or biomaterial dressing and can take up to 10 days for 
suitable attachment of keratinocytes to the dermis [111, 112]. Engineered dermal substitutes 
are typically decellularized organic scaffolds designed to mimic the extracellular matrix of the 
dermis. They can be sourced from cadavers, animals or synthetic biocompatible polymers 
and treated to remove immunogenic compounds [113, 114]. Dermal substitutes tend to have 
a silicone membrane to act as a temporary epidermis [113].  Engineered dermo-epidermal 
substitutes combine both epidermal and dermal biomaterials creating a bi-layered skin 
construct. They have been shown to have good uptakes with a clinical trial conducted using 
Apligraf® showing a 80% graft uptake [115].  
There are a number of advantages and benefits of bioengineered skin constructs. They can 
be used to address serious cases of burns and chronic wounds, particularly where the defect 
exceeds 50-60% of the total body surface [8]. These products address the issues surrounding 
skin donors and can promote the wound healing processes of the patients own body through 
the secretion of growth factors found in the tissue engineered skin construct.  
Whilst tissue engineered skin constructs are advantageous in certain situations, there are a 
number of limitations to their use. These include costs, infrastructure required, poor 
vascularisation through the graft and the inability to resist infections. From a commercial 
point of view, these skin constructs are extremely expensive ranging from $10/cm2 to 
$33/cm2. The average cost to heal a chronic wound defect can add up to approximately 
$2,300 [116]. The high cost can be attributed to the highly specialised infrastructure required 
to source the biomaterials [117, 118], treatment and processing of the materials [109, 117], 
storage facilities [119] and poor shelf life [112]. Whilst clinical trials report high graft uptake 
and wound closure using tissue engineered skin constructs, the vascularisation through the 
graft implant remains quite low. This results in multiple surgeries being required to replace 
old graft with new ones to maintain healing and remove necrotic tissue [9, 10]. Finally, tissue 
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engineered skin constructs are unable to resist infections. In fact, they often act as a 
container for pathogens to proliferate without any interference by the host immune system 
[11].    
2.3.4 Synthetic Skin Scaffolds 
Synthetic skin scaffolds refer to a range of constructs which contain biocompatible polyesters 
and are typically shaped into a 3D porous structure. There has been a significant amount of 
research into the development of synthetic skin scaffolds over the past decade. The ideal 
synthetic skin scaffold would have the following properties [13]: 
• Able to resist infection 
• Able to prevent water loss 
• Able to withstand the shear forces 
• Cost effective 
• Widely available 
• Long shelf life and easy to store 
• Lack of antigenicity 
• Flexible in thickness 
• Durable with long-term wound 
stability 
• Can be conformed to irregular 
wound surfaces and 
• Easy to be secured and applied 
Whilst no wound management product, modern, tissue engineered or synthetic, is able to 
meet all these criteria, synthetic skin scaffolds meet a number of these properties better 
than other counterparts. These include cost effectiveness, ability to withstand shear forces, 
availability, long shelf life and easy storage, lack of antigenicity, flexibility in thickness, 
durable, conformation and ease of application. In addition, antimicrobial characteristics can 
be added to synthetic scaffolds through the loading of antimicrobial compounds into the 
scaffold [14, 120]. Other further criteria synthetic scaffolds should fulfil include facilitation of 
tissue ingrowth and biodegradation allowing for full tissue regeneration of the wound [121, 
122]. There are a large number of published articles on the development of synthetic skin 
scaffolds. More recent articles are summarised in  
 
Table 2-5. 
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Table 2-5: List of recent publications of synthetic skin scaffolds. 
Author/s Scaffold Characteristics References 
Raghavendra 
et al (2013) 
Cellulose-silver nanocomposite 
fibres 
Demonstrates antibacterial 
activity against E. Coli 
[123] 
Veleirinho et 
al (2012) 
Hybrid poly(3-hydroxybutyrate-co-
3-hydroxyvalerate)  
(PHBV)/chitosan nanofibers 
Biocompatible [124] 
Unnithan et al 
(2012) 
Polyurethane and emu oil 
electrospun fibres 
Biocompatible and 
demonstrates minor 
antibacterial activity 
[125] 
Garric et al 
(2012) 
PLA-PEO-PLA type scaffolds Biocompatible and suitable to 
undergo gamma sterilisation 
[126] 
Rnjak-
Kovacina 
(2012) 
Tropoelastin and collagen blend 
electrospun scaffolds 
Mimics the physical, 
mechanical and biological 
components of the skin 
dermis 
[127] 
Franco et al 
(2011) 
Bilayer scaffold consisting of 
electrospun PCL and poly(lacto-co-
glycolic acid) (PCL/PLGA) 
membrane and gluteraldehyde 
(3.5% v/v) cross-linked 
chitosan/gelatin hydrogel 
Overall improved mechanical 
strength, slower 
biodegradation rates and 
minimal swelling compared to 
gels. 
Biocompatible. 
[128] 
Ahn et al 
(2010) 
Collagen scaffold produced by a 3D 
dispensing system supplemented 
with a cryogenic system 
Biocompatible [129] 
Chang et al 
(2008) 
Gravity spun PCL fibers PCL fibers loaded with 
gentamicin which released 
over a number of days 
[130] 
Zhu et al 
(2008) 
Highly porous electrospun mats 
made of collagen  
Biocompatible [131] 
Zhang et al 
(2005) 
Hollow PCL nanofibers with 
therapeutics core 
Able to contain drugs within 
hollow PCL fibres 
[132] 
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2.3.4.1 Production processes 
From  
 
Table 2-5, it is apparent that synthetic skin scaffolds can be produced using a number of 
methods. These include electrospinning, solvent casting, phase inversion, laser excimer and 
thermally induced phase separation [122]. Of these methods, electrospinning appears to be 
the most popular technique. Electrospinning produces fine polymer fibres with a thickness as 
small as 100nm [132]. The process is simple, cost-effective and able to produce fibres with 
various polymers, drugs and other therapeutics. In addition, there is a reasonable potential 
for the process to be upscaled to industrial production. The downside of this process is that 
structures produced by electrospinning tend to be fibrous mats with low porosity and pore 
sizes. 
Another popular technique used is solvent leaching. This process involves using a porogen 
material to act as a mould that can be removed using solvents. Solvent leaching can be used 
to easily create 3D porous structures with high porosity up to 95% [14]. The process takes 
more time compared to electrospinning and requires more technological infrastructure to 
upscale.  
2.3.4.2 Materials 
 
 
Table 2-5 also shows a wide range of biocompatible polymers that have been investigated for 
use in these scaffolds. Some prominent biocompatible polyesters include poly(lactic-co-
glycolic acid) (PLGA) [128], polylactic acid (PLA) [133], polycaprolactone (PCL) [134, 135], 
collagen [136, 137], and chitosan [138]. Of these materials, PCL is a popular choice as it is a 
FDA approved biocompatible polymer with good chemical, mechanical and degradation 
properties [134]. 
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2.3.4.3  Therapeutic loading 
Compared to tissue engineered skin constructs, synthetic skin scaffolds naturally lack 
bioactive compounds to encourage wound healing. Drug loading and elution profiling is an 
important topic in synthetic skin scaffold research, especially studies which load scaffolds 
with antibiotics. The key premise behind antibiotic-loaded scaffolds is the concept of locally 
delivering larger doses of antibiotics to an infection site while avoiding side effects 
commonly associated with systemic antibiotic use as mentioned in 2.3.2.2 Antibiotics [12].  
The simplest method of loading therapeutics onto scaffolds is by soaking the scaffold in a 
solution containing the therapeutic of choice. The therapeutic is adsorbed onto the scaffold 
and is held there by weak electrostatic forces such as hydrogen bonding and Van der Waal 
interactions. The amount of therapeutic loaded onto the scaffold is related to the 
concentration of the therapeutic solution, the time length of soaking, and the available 
surface area. This method is suitable for all therapeutics, especially growth factor proteins 
which may be damaged if loaded using other methods. The limitation of this method lies in 
the poor consistent drug release [14].  
Another popular method is the incorporation of the therapeutic of choice directly into the 
polymer solution prior to scaffold formation. This technique is popular amongst researchers 
who use electrospinning techniques as it involves little change to the method and equipment 
setup. The therapeutic is trapped evenly throughout the scaffold and has a long term drug 
release period spanning multiple weeks [125, 130, 139]. 
One of the more interesting methods of therapeutic loading was described by Zhang et al 
(2005) whereby a bilayer electrospun fibre was produced with an inner core of antibiotic and 
an outer core of PCL [132].The result was high drug loading of the fibres. However, the drug 
release profile suggests that the majority of the antibiotic was released in a very short period 
of time. This would be useful for local delivery of antibiotics to chronic wound infection sites 
but requires another mechanism to prevent reinfection of the wound.    
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2.4 Drug Delivery Systems for Chronic Wounds 
A major component of synthetic skin scaffold development is the loading and delivery of 
therapeutics such as antibiotics and growth factors. There are a large number of drug 
delivery systems developed to address the deficiencies of conventional administration of 
drugs [140]. Over 30% of drugs are delivered using some form of a controlled-release 
technology [141]. Advantages of developing new drug delivery technologies include 
consistent drug delivery to the site of action, prevention of fluctuations in drug 
concentration, reduction in drug dosage, avoidance of side effects, reduced dosage 
frequency and improved patient compliance [142]. 
2.4.1 Drug Elution Profiles 
 
 
Figure 2-4: Schematic representation of different drug delivery systems where (1) sigmoidal release after lag time (2) 
delayed release after lag time (3) sustained release after lag time, (4) extended release without lag time and (5) generic 
pulsatile release. Adapted from Chaudri (2011) [142]. 
Figure 2-4 represents a few drug release profiles. Of particular interest is the extended 
release without lag time as seen in Figure 2-4 (4) which is commonly seen in many drug 
releasing devices, especially drug eluting microspheres [141]. Key features of this logarithmic 
release profile include the burst phase and the sustained phase. . In the burst phase, drug 
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molecules attached to the surface are quickly released into solution typically in a matter of 
hours. Following this, the sustained phase, drug further entrapped in the polymer matrix 
slowly gets released through the gradual degradation of the polymer matrix [141–143].  
With regards to treatment and prevention of microbial infection in wounds, there are a 
number of factors that need to be considered. It is important to ensure that enough 
antibiotic is delivered to the site of action to treat or prevent the infection. This, however, 
does not necessarily mean that every single microbe in the wound must be treated with 
antibiotic. The aim of antibiotic delivery is to reduce bacterial burden in the wound to a level 
that the patient’s immune system can handle. Failure to do so can lead to recurring 
infections and increase the risk of the development of antibiotic resistance [6, 12, 108]. It is 
important to also consider excessively large doses of antibiotics can have a cytotoxic effect 
on the host cells killing them [6, 73].  
2.4.2 Drug Loading Efficiency 
The method of loading drugs onto a delivery vector is just as important as the release 
kinetics, especially when attempting to commercialize the device. Drug loading efficiency is 
one of the main factors to consider. Drug loading efficiency is typically less than 30% 
depending on type of delivery vector, the material used and the concentration of antibiotic 
solution. Hao et al (2011) managed to load the antibiotic chloramphenicol onto lipid 
nanoparticles with a maximum antibiotic loading efficiency of 10.29% [144]. Chang et al 
(2008) achieved a loading efficiency of 18.5% using gentamycin sulphate loaded onto PCL 
nanofibers while Schienders et al (2006) was able to load gentamycin in PLGA microspheres 
in mixture with bone cement with a drug loading of 30% [145]. Another factor to consider is 
whether it the method of loading drugs onto the delivery vector. Typically, loading drugs 
onto vector using a soaking method produces poor loading efficiency and short release 
kinetics. However, incorporating the drug into the vector during its production can reduce 
the rate of release minimizing the effectiveness of the burst phase of the release kinetics. In 
addition, loading drugs using this method limits the type of drug to ones which are 
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compatible with the vector production methods. In general, this rules out most bioactive 
protein molecules [143].   
An ideal drug release profile would treat an infection and prevent further infection until the 
wound heals. Currently, the trend for a burst phase followed by a long sustained phase of 
drug release is adequate. In the burst phase, a large dose of antibiotic can be delivered 
quickly to arrest the growth of bacteria and kill them. It has been determined that bacteria 
must be prevented from colonizing and proliferating before 6 hours past implantation of the 
device [146]. Following this, a long sustained release of antibiotic is useful in preventing 
further infection without interfering with wound healing processes [147, 148].  
2.5 Bioglass 
Bioglass (also known as bioactive glasses) refers to biocompatible and bioresorbable 
ceramics developed by Prof. Larry Hench in 1969 [149]. The material contains SiO2, CaO, 
Na2O, CaF2, and P2O5 in certain ratios. Figure 2-5 shows the potential formulations of Bioglass 
and their respective interaction with hard and soft tissue.  
 
Figure 2-5:  Diagram demonstrating how different concentrations of Bioglass components affect the bioactivity. The zone 
marked by the dashed lines denotes the region where Bioglass supports soft tissue attachment [150]. 
Bioglass is able to form bonds with tissues through the result of a sequence of chemical 
reactions when inserted into living tissues. Briefly, a series of reactions leads to the release 
of soluble ions leading to a formation of a high surface area hydrated silica and 
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polycrystalline hydroxyl carbonate apatite (HCA) bilayer on the surface. This layer enhances 
adsorption and desorption of growth factors which promotes cell compatibility and tissue 
attachment [149, 151].  
Of particular interest is the formulation of Bioglass 45S5 which has been shown to have a 
positive interaction with soft tissues. The name 45S5 signifies the glass composition of 45 wt. 
% of SiO2 and a 5:1 ratio of CaO to P2O5 [150]. In 1981, Wilson et al reported that Bioglass 
45S5 is able to form connections with soft tissue if the interface was immobile. In addition, 
the paper established the safety of using the ceramic in particulate form as well as bulk 
implants [152]. A more recent study by Gillette found that Bioglass 45S5 can increase tissue 
strength which could be beneficial in the treatment of wounds [153]. Another benefit of 
Bioglass 45S5 is its ability to stimulate angiogenesis leading to new blood vessel formation 
[154]. 
2.5.1 Bioglass 45S5 Scaffolds 
Bioglass 45S5 has been used in the creation of synthetic skin scaffolds in a number of ways. 
Most recently, Bioglass 45S5 nanofibers have been created using an electrospinning process. 
The resulting material is pliable and has a rapid degradation rate making it useful for soft 
tissue regeneration such as that of chronic wounds [96, 155]. Other scaffolds involving the 
use of Bioglass 45S5 include a PDLLA/Bioglass 45S5 foam composite shown to be compatible 
with human lung epithelial type II cells [156], and a Bioglass 45S5/PCL composite scaffold 
primarily for bone regeneration [157]. 
2.5.2 Bioglass 45S5 Antimicrobial Properties 
Bioglass 45S5 is capable of exhibiting some antimicrobial activity as mentioned in a number 
of articles [158–160]. The mechanism for the antimicrobial effect comes from the release of 
basic products during degradation which increases the pH of the local environment. It should 
be noted that the antimicrobial properties have only been demonstrated in vitro where there 
is a high concentration of bioglass 45S5. A study by Xie et al found that particulate bioglass 
45S5 did not prevent Staphylococcus aureus infections in open tibial fractures on rabbits 
[161].  
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Antimicrobial properties of Bioglass 45S5 can be enhanced through the doping of 
antimicrobial ions such as silver, zinc and copper. Silver, whose antimicrobial properties are 
mentioned in 2.3.2.1.1 Silver, can be added to Bioglass 45S5 in nanoparticles of AgO2. A 
study of surgical sutures coated with Bioglass 45S5 doped with 3 wt% AgO2 demonstrated 
reduced bacterial attachment under flowing conditions [162].  
2.6 Drug Eluting Bioglass 45S5 Microspheres 
Bioglass 45S5 has numerous properties which make it ideal to use as a carrier for drugs. It is 
biocompatible, bioresorbable with controllable degradation and offers suitable surface 
chemistry for cell attachment, proliferation and differentiation. In addition, Bioglass 45S5 is 
able to withstand a certain amount of mechanical force making it ideal for bone tissue 
engineering [163]. Bioglass 45S5 can also be combined with polymers to create a composite 
system that provides more mechanical flexibility and easier processing capabilities [156]. 
Whilst Bioglass 45S5 has been demonstrated to also have antibacterial effect [158, 160, 164, 
165], further investigation has found that this is generally only the case where there is a high 
weight percentage of bioglass 45S5 particles to bacterial broth volume. The mechanism of 
the antibacterial effect is due to the increase in pH from the leaching of ions from the 
Bioglass 45S5 [158, 160]. This can have a negative effect on host cells. Bioglass 45S5 activity 
against biofilm forming bacteria has also been investigated, but further research is required 
to link lab experimental results to clinical results [159]. 
Bioglass 45S5 microspheres are one of the many forms that have been investigated for 
delivering drugs, particularly antibiotics. For soft tissue purposes, it is beneficial to have 
Bioglass 45S5 in the form of microspheres for a number of reasons. Bioglass 45S5 
microspheres are easier to manufacture when compared to making Bioglass 45S5 scaffolds 
which are more suited for hard tissue engineering. Secondly, microspheres loaded with drugs 
are easier to incorporate into polymer scaffolds which can be done using thermal adhesion 
or direct addition of microspheres to the polymer scaffold processing. Finally, microspheres 
have a greater surface area compared to other structures allowing for greater drug loading.  
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Drug loading onto Bioglass 45S5 microspheres can be accomplished in a number of ways. Sol-
gel technology allows drugs, proteins and other biologically active molecules to be 
incorporated into the bioglass 45S5 in a room temperature process [166]. Radin et al [166] 
demonstrated how the antibiotic vancomycin can be loaded onto silica discs. Issues with  this 
process include long processing time up to 3 days, extremely low pH (pH 2.5 – 3) involved 
which may exclude the ability  to load proteins and the large amounts of monitoring required 
[166]. Another approach is to soak the bioglass 45S5 in a solution of the desired loading 
molecule allowing the molecule to attach to the surface [167]. This results in low drug 
loading efficiencies, even with surface modifications such as mesopores to increase total 
surface area [167]. Finally, chemical bonding can be achieved through the interaction of 
hydroxyl and amino groups of molecules with the Si-OH and P-OH groups present on 
bioactive glasses [168]. However, it should be noted that antibiotics only work when they are 
taken up by bacteria cells meaning that the chemical bond must be cleaved or the molecule 
released in some mechanism [6]. Incorporating antibiotics during traditional bioglass 45S5 
production is generally dismissed due to the high temperature involved which can incinerate 
antibiotics [166].  
Another method of loading drugs onto bioglass 45S5 microspheres is through the use of 
hollow mesoporous microspheres. A hollow mesoporous microsphere significantly increases 
the total surface area of the microsphere allowing for greater drug loading. In addition, it can 
be combined with a polymeric or gel –like filler to decrease the initial mass and rate of drug 
eluted allowing for longer sustained release. An optimal configuration of the microsphere 
would be to have antibiotic solution trapped inside a hollow microsphere. The size and 
number of mesopores could theoretically be used to control the release of antibiotic solution 
until the Bioglass 45S5 degrades allowing for the remaining antibiotic to be released. 
Combined with antibiotic attachment to the surface and mesopores channels, this design 
setup could potentially create a double burst profile of antibiotic release which would be 
useful in treating infected chronic wounds.  
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There are few articles which investigate this setup. Most bioglass 45S5 microspheres 
represented in literature are mesoporous but not mesoporous and hollow. Also, there are no 
articles on loading antibiotics or drugs as a solution inside hollow Bioglass 45S5 
microspheres. An article by Fu et al in 2011 [169] developed hollow hydroxyapatite 
microspheres which were loaded with bovine serum albumin in a similar setup as described 
previous paragraph and depicted in Figure 2-6. The antibiotic solution was loaded using a 
soaking procedure assisted with a vacuum chamber. The setup used by Fu cannot be exactly 
copied using Bioglass 45S5 as hydroxyapatite ceramic is naturally porous as opposed to 
Bioglass 45S5 which is solid [169]. 
 
Figure 2-6:  (a) Optical image of starting glass (CaLB3-15) microspheres, and SEM images of (b) external surface of hollow 
HA microsphere prepared by converting the glass microspheres for 48 h in 0.02 M K2HPO4 solution at 37°C and pH = 9, (c) 
cross section of hollow HA microsphere [169]. 
2.7 Commercial Products of Microsphere Drug Delivery Systems 
The commercial market for drug delivery systems was $47 billion in 2002 has been growing 
ever since. There are a number of devices on the market for controlled release drug delivery 
ranging from insulin pumps to biodegradable polymeric microspheres. There are over 30 
companies involved with polymeric drug delivery systems. Examples of commercial 
microsphere products include Lupron Depot® and Nutropin Depot®. Lupron Depot® delivers 
luprolide acetate in PLG microspheres to treat prostate cancer, endometriosis, fibroids and 
central precocious puberty [170, 171]. Nutropin Depot® delivered recombinant human 
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growth hormone (rhGH) encapsulated in PLG microspheres to treat growth hormone 
deficiencies [172, 173].  
The major concern of biodegradable polymeric microspheres is the highly complicated and 
technical manufacturing and production requirements which incur significant costs. Nutropin 
Depot® was removed from the market because of the high costs and poor uptake of the 
device [174].  
Future markets that controlled release biodegradable microspheres have been tapped into 
include controlled-release vaccines [175], stabilisation of encapsulated protein therapeutics 
[176, 177]and DNA encapsulation for gene therapy [178]. In addition, these microspheres 
have been investigated for developing new delivery vectors for therapeutics through the 
respiratory tract [179, 180].  
2.8 Summary of Literature Review 
Chronic skin wounds are a serious health issue which affect a significant proportion of 
society in developed countries, particularly amongst the elderly, indigenous and rural 
communities. The major complication associated with chronic wounds is infections. 
Currently, there is a large spread of medical products used to treat chronic wounds from 
traditional wound dressings to modern tissue engineered skin constructs. These forms of 
treatment are generally conducted with the addition of antimicrobial agents or 
administration of systemic antibiotics. There are no commercial products in which the 
dressing itself is capable of long term antibiotic release. Emerging research in this area 
focuses on the development of synthetic skin constructs which can be loaded with drugs, 
growth factors or other biological compounds. One method of drug loading and delivery 
involves the use of bioactive resorbable glass microspheres which could be tailored to hold 
high quantities of drugs. Drugs can be attached to the surface and pores of the microsphere, 
or encapsulated within the microsphere within a hermetic seal. Currently, polymeric 
microspheres have been used in treatments of cancer, diabetes, and growth hormone 
deficiencies. Furthermore, other potential markets include vaccine therapy, protein 
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therapeutics and DNA gene therapy. There are no commercial bioactive glass ceramic 
microspheres on the market.  
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3 Design Process 
3.1 Introduction 
As outlined in the literature review, there is a need for effective chronic wound treatments 
which addresses device uptake, combats infections and reduces overall wound healing time. 
Synthetic skin substitutes have the potential to address all these issues in a single product. 
For this thesis, an investigation will be carried out to the development of a synthetic skin 
scaffold containing antibiotic-loaded bioactive glass microspheres. 
In order to develop a device which sufficiently treats chronic wounds, it is important to 
identify the user requirements and design risks involved in synthetic skin scaffolds which 
contain antibiotic-loaded bioglass 45S5 microspheres. There are a number of user 
requirements related to the device which includes clinical and mechanical needs. It is also 
important to identify potential design risks which could pose hazards to users of the device. 
The synthetic skin scaffold to be developed in this thesis combines the technology of 
synthetic polycaprolactone scaffolds and bioglass 45S5. These scaffolds are three 
dimensional, porous polyester scaffolds which promote vascularization and tissue regrowth 
[181]. Its high surface area and low glass transition temperature make it an ideal carrier of 
bioglass 45S5 microspheres which can be attached to the surface of the scaffold.  
Bioglass 45S5 microspheres enhance cell attachment to the scaffold and can be modified to 
load drugs such as antibiotics to create a long-term antimicrobial environment. A number of 
bioglass 45S5 microsphere design iterations will be explored in this chapter. In addition, 
similarities and differences between bioglass 45S5 and sodium borosilicate glass will be 
addressed to show that sodium borosilicate microspheres can be used as an analogue for 
bioglass 45S5 microspheres in experiments. 
This thesis aims to explore design modifications to bioglass 45S5 microspheres, methods of 
attaching bioglass 45S5 microspheres to the scaffold and how these modifications can be 
used to load and release antibiotics. From the results, enough information should be 
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available to verify the ability of a synthetic skin scaffold with antibiotic-loaded microspheres 
to be used to treat chronic skin wound conditions. 
3.2 User Requirements and Design Risk Assessment 
3.2.1 User Requirements 
A user requirement table outlines the specifications a product should meet as part of its 
functionality. These specifications can come from a wide range of sources which includes 
users and regulatory standards. Since the device to be developed in this thesis is within early 
development stages, user requirements will be focused on specifications required for the 
device to act primarily as a wound healing device, secondly as a wound healing device 
capable of treating infections and thirdly as a wound healing device capable of sustained 
antimicrobial activity.  
Table 3-1 lists the clinical and mechanical requirements for a synthetic skin scaffold with 
antibiotic-loaded microspheres. Each user requirement is given a unique identifying number 
(UIN) and assigned a priority ranking of I, II or III.  Priority ranking of I describes requirements 
needed to ensure the device is able to be used in chronic wound healing. Priority ranking of II 
addresses functions of the device which would allow it to additionally treat and maintain a 
level of antimicrobial activity. Priority ranking of III refers to requirements which are not 
necessary but would enhance the effectiveness of the device.  
Chronic wounds sizes vary significantly in width, depth and contour. It is important that the 
scaffold is able to fit into the majority of major chronic wounds. In addition, for each 
individual wound, there should be minimal modifications required to make the scaffold fit in 
the wound. 
A major issue with the wound healing of chronic wounds is the vascularization of the device 
replacing the degraded skin. Vascularization, as explained in 2.2.1.3.2 Angiogenesis, is 
necessary for tissue growth and host antimicrobial activity. 
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Table 3-1: User requirement table 
Unique 
Identifying 
Number (UIN) 
User requirement 
Priority 
Ranking: I, II 
or III 
 
 
Clinical 
UR1 Able to fit a wide range of wounds I 
UR2 Encourages vascularization and tissue regrowth I 
UR3 Deliver antibiotics locally to the wound site II 
UR4 Maintain a sustained antimicrobial environment II 
UR5 Seal the wound from the external environment III 
 
 
Mechanical 
UR6 Stiffness of entire assembly is less than the modulus of skin tissue I 
UR7 Scaffold must not fragment or degrade during wound healing I 
UR8 Biodegrade upon wound closure I 
 
 
Other 
UR9 Low Production Time III 
In the early stages of wound healing using skin devices, there is a significant risk of infection. 
Currently, antibiotics are administered intravenously. However, if there is low vascularization 
of the wound, there may be a diminished antibiotic effect. For a synthetic scaffold, it would 
be ideal if the antibiotic was locally delivered with the scaffold using an appropriate delivery 
vector such as microspheres.  
It is ideal if the wound maintains an antimicrobial environment whilst tissue regeneration 
occurs. This can be achieved by having a sustained antibiotic delivery system capable of 
week-long antibiotic delivery. Simultaneously, the solution needs to support granular tissue 
formulations.  
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To help maintain sterility and prevent further infection, an external seal should also be 
applied to protect the wound from the external environment. This can be done in a number 
of ways which may or may not be coupled with the scaffold device.  
The scaffold should have a similar elasticity to the surrounding skin. Large differences in 
elasticity can promote pain, wound erosion and increase wound healing time.  
The scaffold should also maintain structural integrity whilst wound healing is occurring. 
Degradation in structure could hinder vascularization and tissue regrowth.  
Once tissue growth and wound closure is achieved, the scaffold will be integrated with the 
skin and become irremovable. The scaffold should biodegrade allowing full restoration of 
skin tissue.  
Another user requirement would be low production time and costs to allow the device to be 
a cost-efficient competitive product amongst all the other wound healing products on the 
market.  
3.2.2 Design Risk Assessment 
A design risk assessment helps to identify factors or events which could impede the function 
of the device to act as a chronic wound healing product. As seen in Table 3-2, each risk is 
given a likelihood and severity number ranging from one to five where one is minimum and 5 
is maximum. The likelihood and severity ratings are multiplied to give an importance rating 
out of a maximum of 25. The higher the importance rating, the more significant the risk is. 
Table 3-2: Importance rating system 
 Severity 
1 2 3 4 5 
Likelihood 
1 Acceptable Acceptable Acceptable Moderate Moderate 
2 Acceptable Acceptable Moderate Moderate Moderate 
3 Acceptable Moderate Moderate Moderate Severe 
4 Moderate Moderate Moderate Severe Severe 
5 Moderate Moderate Severe Severe Severe 
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Table 3-3 lists design risks associated with using a synthetic skin scaffold with antibiotic-
loaded microspheres. These include biological risks the device may induce once used and 
design risks which affect the functionality and effectiveness of the device to perform its use. 
Table 3-3: Design Risk table 
Unique 
Identifying 
Number (U.I.N) 
Risk Assessment Likelihood (1-5) 
Severity 
(1-5) 
Importance 
(Likelihood 
x Severity) 
Biological risks 
RA1 Biological rejection of scaffold 2 5 Moderate 
RA2 Adverse reactions to antibiotics 2 5 Moderate 
RA3 Microbial infections and colonization of the scaffold 4 5 
Severe 
Design Risks 
RA4 Unable to make bioglass 45S5 microspheres 2 4 Moderate 
RA5 Scaffold destruction during microsphere attachment 3 4 
Moderate 
RA6 Unsecure microspheres attached to scaffold 4 2 
Moderate 
RA7 Unable to load antibiotics onto microspheres 1 5 
Moderate 
RA8 Unable to deliver sustained antibiotic release (< 1 week) 4 3 
Moderate 
RA9 
Unable to maintain scaffold 
integrity during cyclic loading 
tests 
3 4 Moderate 
 
Biological rejection of the scaffold could arise from a number of issues. In graft constructs, 
this is due to the incompatibility of the major histocompatibility complex cell surface 
receptors between the host and graft leading to immune rejection. For synthetic scaffolds, 
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where there are no surface receptors involved, rejection can occur due to non-biocompatible 
materials used and infections present in the wound. 
Adverse reactions to antibiotics present in the microspheres are an issue which needs to be 
considered. Ideally, a patient with allergies to certain antibiotics would be known 
beforehand. However, careful monitoring of the patient would be required as standard 
practice. As the antibiotic is loaded onto the microspheres as opposed to the scaffold, a 
change of antibiotics is possible and would only be limited to the time it takes to load 
antibiotics and attach microspheres to the scaffold. 
Microbial infections are a major source of concern. Untreated infections can result in scaffold 
rejection, worsening condition of the chronic wound and decline in patient health. 
Antibiotics loaded with the scaffold need to be able to release a sufficient amount of drug to 
treat the infection and prevent further infection during wound healing. 
A key part of this thesis is the production of bioglass 45S5 microspheres. Currently, the most 
popular method of making bioglass 45S5 microsphere is using the sol-gel technique which 
requires up to 3 days. An alternative method is to flame spray the microspheres and collect 
them. This method would only require a few minutes to complete. 
Microspheres would ideally be adhered to the scaffold by taking advantage of the low glass 
transition phase of the scaffold. However, due to the micron size struts, the scaffold can 
easily undergo heat damage reducing porosity. This would in turn reduce the capability of 
vascularization throughout the scaffold.  
On the contrary, poor microsphere attachment could lead to migration of microspheres 
through the skin tissue away from the wound site through muscle contractions. This could 
lead to issues regarding localized treatment of infections. 
Another key part of this thesis is the loading and release of antibiotics from bioglass 45S5 
microspheres. Ideally bioactive glass microspheres and any modifications to the 
microspheres would be able to have a high drug loading efficiency and sustained release.  
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Regarding sustained release, the ideal time length of the sustained release period is equal to 
the time required for the chronic wound to heal. However, due to the varying size and 
conditions of chronic wounds, there will always be a discrepancy between the two periods. 
Initial development would focus on a week-long release period.  
Finally, the scaffold should maintain structural integrity during wound healing. Whilst wound 
dressings over the chronic wound site should minimize movement of the scaffold, it would 
be ideal of the scaffold itself is able to maintain form over 50% elastic deformations whilst 
vascularization and tissue regrowth occurs through the scaffold.  
3.3 Design Rationale 
Section 2.3.4 Synthetic Skin Scaffolds from the literature review outlines the ideal general 
properties of synthetic scaffolds, how they are produced and what materials scaffolds are 
made from. Scaffolds produced by solvent leaching have a greater interpenetrating network 
with a porosity of greater than 95%. PCL scaffolds are popular due to the well-known 
biocompatibility and FDA approval of the polyester. Methods of loading drugs onto scaffolds 
are outlined in section 2.3.4.3 Therapeutic loading. Most methods involve a single scaffold 
unit with antibiotics loaded directly onto the scaffold. This results in a sustained release 
lasting only a few days. So far, there has been no research into a two part device in which 
antibiotics are loaded onto a delivery vector which is attached to the scaffold. 
A two-part synthetic skin construct is proposed in this thesis. It consists of a PCL scaffold 
utilizing a bioglass 45S5 microsphere as a delivery vector for antibiotics. 
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3.3.1 Scaffold 
 
Figure 3-1: PCL scaffolds 
The scaffold for the device, as seen in Figure 3-1, is made using a PCL solvent leaching 
technique. The scaffold has an interpenetrating network of channels creating a matrix with 
greater than 95% porosity. This allows proliferating cells to infiltrate throughout the scaffold, 
attach and proliferate. The high porosity of the scaffold is achieved using a unique porogen 
which the scaffold is moulded around. This interpenetrating network of channels has been 
shown to accelerate the revascularisation of the wound site within two weeks in animal 
studies [181]. In addition, the scaffold has elasticity similar to skin which is necessary to 
optimise skin regeneration and provide mechanical strength to the wound region. 
 
Figure 3-2: Bioactive glass powder granules 
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In addition to the scaffold, Bioglass 45S5 powder of less than 50 µm diameter is coated onto 
the surface of the scaffold. Bioglass 45S5 powder, described in detail in 2.5 Bioglass, 
encourages the attachment of cells to bioinert surfaces increasing the rate of uptake of the 
scaffold in the skin and reducing wound healing time. In addition, bioglass 45S5 dissolution 
products neutralize the acidic degradation products of PCL.  
Previous research involving polycaprolactone scaffolds has looked at the addition of 
antibiotics to the scaffold as a means of treating and preventing infections. Scaffolds have 
been loaded with chloramphenicol and tetracycline using a soaking protocol and various 
scaffold modifications to delay antibiotic release and prolong the sustained release period. 
However, the studies found that the majority of antibiotic was released within 2 hours 
followed by a very low amount of antibiotic release over 24 hours. Other issues identified 
were poor shelf life due to the degradation of antibiotics over time, and large losses of 
antibiotic during manufacturing  [14, 182]. 
Following on from these studies, a change in the design was made to separate the antibiotic 
delivery vector from the scaffold creating a two-part product. Antibiotics would be loaded 
onto bioactive glass microspheres which in turn would be adhered to the scaffold prior to 
clinical use. Adhesion of the microspheres to the scaffold would be performed using a 
thermal attachment process where the scaffold is heated enough to allow the microspheres 
to bind to the scaffold surface. Advantages of using this system include longer shelf life of 
scaffolds, control over dosage concentration for medical staff, and potentially more 
sustained antibiotic release.  
3.3.2 Microspheres 
3.3.2.1 Synthesis 
Bioactive glass microspheres can be made from various methods. One of the more popular 
methods is through sol-gel techniques. Briefly summarizing the technique, metal organic and 
metal salt precursors undergo hydrolysis and poly-condensation reactions to form a gel over 
a period of several days. The gel is then dried at 600-700°C to form the glass.  Bioglass 45S5 
microspheres can be designed using through the addition of polymer molecules capable of 
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self-assembling into microspheres such as chitosan [183]. Problems associated with this 
technique include the long processing time [166] and the fragile nature of the chemical 
reactions which can be interfered by slight changes in pH and precursor concentrations 
[184].  
Instead of using sol-gel techniques, bioglass 45S5 powder will be transformed into 
microspheres through the use of an oxy-acetylene flame gun [185, 186]. This significantly 
speeds up the process allowing the creation of microspheres from raw materials to be 
processed within a day. Particle size of bioglass 45S5 microspheres can be easily controlled 
through the input of controlled sized powder. In addition, this process can be easily upscaled 
to mass manufacturing [187].  
3.3.2.2 Microsphere configurations 
Ceramic microspheres have been investigated as potential delivery vectors for antibiotics 
and were reviewed in length in section 2.6 Drug Eluting Bioglass 45S5 Microspheres. There are 
a number of design considerations which need to be taken into consideration. They include: 
• High surface area for antibiotic loading via electrostatic and weak intermolecular 
bonding 
• Ease of manufacturing 
• Capability for long term antibiotic release 
 
 
Table 3-4 lists a number of microsphere design iterations that could be used for antibiotic 
loading. Microsphere designs are listed from simple to complex iterations listing the 
advantages and disadvantages of each iteration. 
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Table 3-4: Bioglass 45S5 microsphere configurations. 
# Microsphere design 
Image cross-
section 
depiction 
Advantages Disadvantages 
1 Normal 
 
 
 
 
 
Low technology 
requirements to 
produce 
 
Low surface area for 
antibiotics to attach to 
compared with other 
design iterations 
2 Porous 
 
 
 
 
 
Increased surface area 
compared to normal 
microspheres 
Requires further 
treatment to create pores 
Longer production time 
3 Hollow (intact) 
 
 
 
 
 
Potential to load 
antibiotic solution 
within a hermetically 
sealed bioglass 45S5 
microsphere 
 
Getting antibiotic solution 
inside hollow microsphere 
is extremely difficult 
 
4 Hollow (porous) 
 
 
 
 
 
Greater surface area 
 
Requires further 
treatment to create 
porosity 
5 
Hollow 
(porous) 
with gel 
center 
 
 
 
 
 
 
Prolongs antibiotic 
release period 
Capable of loading 
more antibiotic 
through gel center 
Increases production time 
significantly 
Gel core may cause 
bioglass 45S5 to undergo 
degradation reactions, 
especially if it holds water 
 
6 Coated 
 
 
 
 
 
 
Polymer coating 
prolongs antibiotic 
release and delays 
bioglass 45S5 
degradation 
Bioglass 45S5 surface not 
available for interaction 
with cells until polymer 
coating degrades. 
Antibiotic may be lost 
during polymer coating 
process 
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The first design iteration is normal spherical microspheres. It should be possible to 
manufacture these microspheres from bioglass 45S5 powder using a flame-spray gun. Whilst 
microspheres have high surface area to volume ratios, other design iterations offer more 
surface area which allows for greater antibiotic loading.  
Design iteration 2 builds on the first design iteration by increasing the surface area of the 
microsphere by introducing pores into the surface. Pores can be etched into the microsphere 
using highly basic solutions such as hydroxide solutions. At high temperature, alkali solutions 
can etch bioglass 45S5 through the following chemical reaction. 
 
Equation 1: Chemical Etching reactions of Bioglass 45S5 with potassium hydroxide (KOH) solution. 
 
Chemical etching is time and heat intensive process requiring up to a day for processing 
depending on the strength of the alkali solution. Focused ion beam techniques could also be 
used to create pores on the surface of microspheres although the technique is highly 
technical and not easily upscaled. 
Hollow microspheres are a byproduct of flame-spray. It is believed that certain compounds 
within the bioglass 45S5 powder react to produce gas at high temperatures. If the 
microsphere is cooled fast enough, the gas remains trapped within microsphere. It is 
theorized that with a modification to the process, liquid solutions of antibiotics could 
potentially also be trapped within the microspheres creating a ceramic hermetically sealed 
antibiotic solution delivery vector. 
Design iteration 4 combines iterations 2 and 3 to create a hollow porous microsphere. This 
greatly increases the surface area available for antibiotic loading. However, producing these 
microspheres would require a balance between chemical etching technique and size of the 
inner diameter of the microsphere else risking complete dissolution of the microsphere.  
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Design iteration 5 builds on iteration 4 with the addition of a gel to lock in antibiotic bound 
to the inner surfaces of the microsphere. The gel itself could be used to load more antibiotic 
increasing the total antibiotic load per microsphere. This would prolong antibiotic delivery as 
either antibiotic molecules move through the gel or remain locked until the gel degrades 
exposing the inner surfaces. Other factors which would affect antibiotic release is the 
viscosity of the gel, the degradation rate and water solubility of the gel.  
Design iteration 6 describes any of the previous design iterations with the addition of a 
polymer coating to prolong antibiotic loading and delay degradation. The polymer coating 
would also be useful for scaffold adhesion if the coating polymer is the same as the scaffold 
polymer and if the polymer is thermo-adhesive. Problems associated with polymer coatings 
include the restriction of bioglass 45S5 surface for cell attachment and the potential of 
antibiotic loss to occur during the polymer coating phase.  
For this thesis, design iterations 1, 2 and 3 will be investigated. These iterations were chosen 
as they provide the groundwork for design iterations 4, 5 and 6. Design iterations 4, 5 and 6 
and other further work could form the basis of a follow-up Masters or PhD project.  
3.3.3 Bioglass 45S5 vs Sodium Borosilicate Microspheres (Q-cells) 
The primary design of the synthetic wound healing device described in this thesis is to use 
Bioglass 45S5 microspheres as the carrier for antibiotics. However, due to difficulties in 
sourcing Bioglass 45S5, sodium borosilicate microspheres have been used as an analogue for 
bioglass 45S5 microspheres in some experiments. Hence it is important to note the 
differences between Bioglass 45S5 and sodium borosilicate microspheres as shown in Table 
3-5. 
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Table 3-5: Similarities and differences between Bioglass 45S5 and sodium borosilicate microspheres. 
Similarities Differences 
• Both amorphous silicate-based  
material 
• Similar mechanical, chemical 
and thermal properties 
• Antibiotic loading primarily 
through electrostatic/weak 
intermolecular forces 
• Sodium Borosilicate is hydrophobic 
while Bioglass 45S5 is hydrophilic 
• Slight compositional differences leads 
to differences in the rates of 
hydration of silicate compounds. 
 
 
For the purposes of microsphere attachment to scaffolds and primary method of loading 
antibiotics to microspheres, the two materials are quite similar in their characteristics. The 
biggest difference between the materials is that sodium borosilicate microspheres are 
hydrophobic while Bioglass 45S5 microspheres are hydrophilic. To compensate for the 
differences, ethanol has been used in conjunction with water in some experiments to mimic 
the conditions and behaviors of bioglass 45S5 microspheres in water. A minor difference 
between the two materials is that Bioglass 45S5 can form a gel layer if it is exposed to water 
for a long time. This is part of the process of bioglass 45S5 dissolution that releases bioactive 
compounds to attach cells to bind to surfaces. Sodium borosilicate microspheres do not 
dissolve in water. The scope of this thesis does not expand far enough for this difference to 
have a significant effect on experimental procedures and data.  
3.4 Experimental Philosophy 
Section 3.2 User Requirements and Design Risk Assessment identifies some key 
requirements and concerns regarding synthetic skin scaffolds. A combination of literature 
review articles and experiments will be used to adequately address these points. 
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Table 3-6: Assessment of user requirements and risk assessment from literature review 
UIN Requirement or Risk Literature References 
UR1 Able to fit a wide range of wounds 
Scaffolds are able to be shaped to 
fit wounds either through pre-
forming or post-formed 
modifications. 
[181] 
UR2 
Encourages 
vascularization and 
tissue regrowth 
Scaffold has been shown to 
encourage vascularization in 
animal models 
[181] 
UR5 Seal the wound from the external environment 
Separate wound dressings can be 
used to help seal the wound [94, 188] 
UR6 
Stiffness of entire 
assembly is less than the 
modulus of skin tissue 
Modulus of scaffold ranges 
between 20-60 kPa [181, 182] 
UR8 Biodegrade upon wound closure 
PCL and Bioglass 45S5 are 
biocompatible and biodegradable [134, 149, 151] 
UR9 Low Production Time 
Scaffold production time is 3 days 
when operations are conducted 
in serial progression 
[181] 
RA1 Biological rejection of scaffold 
PCL and bioglass 45S5 are 
biocompatible, biodegradable 
and shown to encourage 
vascularization in animal models. 
[134, 149, 151, 
181] 
RA2 Adverse reactions to antibiotics 
Antibiotic sensitivity will need to 
be confirmed before use. 
Antibiotic microspheres can be 
left out of the device if necessary.  
[189] 
 
Table 3-6 addresses as many user requirements and risks as possible from using information 
from the literature review. User requirements and risk assessments listed in Table 3-6 are 
recognized as issues which have already been addressed in other research articles.  
Scaffolds for wound healing should be able to fit a wide range of wound sizes and depth. 
Scaffolds are able to be produced in a wide range of shapes within a three day production 
phase. In addition, the scaffolds are soft to be manually cut within surgery to fit the wound.  
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Scaffolds have also been shown to encourage vascularization throughout the scaffold in non-
apoxic wounds in animal models. Full tissue regrowth is achieved within 1 week of 
implantation [181].  
Protecting the wound from the external environment is important for preventing further 
infection and maintains wound moisture levels. Whilst the device doesn’t currently account 
for this, there are many wound dressings which are also commonly used in conjunction with 
skin constructs.  
The Young’s modulus of the device should be less than the modulus of the surrounding skin 
in order to prevent abrasion and pain. The modulus of the scaffold ranges between 20-60 
kPa as it becomes compressed which should be lower than the modulus of the surrounding 
skin.  
Since the scaffold will integrate fully with new tissue, it cannot be removed and must 
biodegrade. Multiple journal articles show that PCL scaffolds and Bioglass 45S5 microspheres 
are biodegradable which is necessary for synthetic wound healing devices [134, 149, 157].  
The production time of the device is important in terms of manufacturing, product turnover 
and being commercially competitive. Scaffolds used in this thesis have a three day 
production time if the processes are executed in serial sequence. It is possible for the 
production to be greatly reduced if processes involved are performed in parallel. The 
production time of bioglass 45S5 microspheres will be investigated in the experiments in 
Chapter 4: Production and Characterisation of Microspheres. 
As mentioned before, the materials used in the device are biocompatible and biodegradable. 
In addition they are able to promote vascularization and granular tissue formation within a 
week of implantation.  
Adverse reactions to antibiotics are a serious issue. Antibiotic sensitivity needs to be 
confirmed by the clinician before use of the device. Since the device consists of two parts, it 
is possible for the scaffold to be kept separated from the antibiotic loaded microspheres. 
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While antimicrobial activity won’t be present from the scaffold, infections can be treated 
through I.V. antibiotic administration or through other antimicrobial products.  
Table 3-7: Experimental process  
# Experiments Relevant UINs Pass/Fail/ Incomplete 
 Chapter 4 - Production and Characterisation of Microspheres 
4.1 Production of Bioglass 45S5 microspheres 
UR3, UR4, UR9, 
RA4 
 
4.1a  Whole  
4.1b  Hollow  
4.1c  Porous  
4.2 Able to load antibiotics within hollow microspheres UR3, UR4  
4.3 Standardize particle size UR3, UR9  
 Chapter 5 - Microsphere Attachment Studies 
5.1 Able to attach microspheres to scaffold UR2, UR3, RA5  
5.2 Maintain scaffold integrity during attachment process UR7, RA5, RA6  
5.3 Maintain scaffold integrity during cyclic loading test UR7, RA9  
 Chapter  6 - Drug Release Studies 
6.1 Able to load antibiotics onto microspheres 
UR3, RA7, RA8 
 
  Able to load antibiotic-loaded microspheres onto scaffolds  
6.2 Release of antibiotic from device 
UR4, RA8 
 
6.2a  1 day  
6.2b  1 week  
6.3 Reliable release of antibiotics from device UR3, UR4  
 
Table 3-7 lists the experiments that will be performed in this thesis and the relevant user 
requirements and risks which will be answered by these experiments. A completed version 
of this table will be addressed in section 7 General Discussion. 
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Chapter 4 of this thesis focuses on the production of different types of microspheres. As 
stated in section 3.3.2.2 Microsphere configurations, whole, porous and hollow 
microspheres will be attempted to be produced. In addition, an attempt to load liquid into a 
hermetic-sealed hollow microsphere will be conducted to determine the feasibility of 
producing hollow microspheres with antibiotic solution within. Characterization studies of 
the particle sizes of the microspheres will be carried out. 
Chapter 5 focuses on the attachment of microspheres to the scaffold. During microsphere 
attachment to the scaffold, there is a potential for the scaffold to lose structural integrity 
through heat damage. Experiments on how heat affects microsphere attachment and 
scaffold damage will be carried out. In addition, once microspheres have been attached to 
the scaffolds, a cyclic loading test will be carried out to determine the percentage of 
microspheres lost during 50% elastic compression at 1.5Hz for 24 hours. 
Chapter 6 involves the study of drug release from microspheres attached to the scaffold. 
Chloramphenicol antibiotic will be loaded onto microspheres through a soaking technique. 
The loaded microspheres will then be attached to scaffolds. Drug release from the device will 
be monitored using a UV spectrophotometer calibrated to detect release of chloramphenicol 
molecules.  
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4 Production and Characterisation of Microspheres 
4.1 Introduction 
This chapter will explore the production of three types of microsphere design iterations; 
whole, hollow and porous. In addition, experiments will be conducted to investigate the 
potential of creating an antibiotic-solution filled microsphere through flame-spray 
techniques.  
The primary production method for microspheres used in this chapter will involve the use of 
a flame-spray setup. Two types of flame guns, Thermospray Type 5P and SuperJet S, were 
used to produce bioglass 45S5 microspheres from bioglass 45S5 powder. Thermospray Type 
5P is a hand-held industrial flame gun commonly used to deliver metal coatings on large 
surfaces. SuperJet S is a smaller hand-held flame gun that is typically used for metal coating 
small hard to reach surfaces with its long narrow barrel.  
Characterization of microspheres produced in using flame-spray processes will involve 
optical microscopy, image analysis, and scanning electron microscopy (SEM).  
4.2 Methodologies 
4.2.1 Materials and Equipment 
Bioglass 45S5 powder (<40µm) was produced in the University of Sydney. Sodium 
borosilicate microspheres were sourced from Barnes (Q-cell 520, Barnes). Flame spraying 
was performed using two types of flame guns, a Thermospray Type 5P (Metco) and a 
SuperJet S (Eutalloy). A paint spray gun (Metabo) was used to deliver red dye into the path of 
the flame for experiments to test the validity of loading antibiotic solutions inside a 
hermetically sealed hollow bioglass 45S5 microsphere.  
Potassium hydroxide (KOH) was sourced from Sigma Aldrich. Optical microscopy and particle 
size analysis was performed using a Leica DMRXE upright microscope and Leica Qwin Image 
Analysis Software. Scanning Electron Microscopy was carried out at the Australian Centre for 
Microscopy and Microanalysis (ACMM). 
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4.2.2 Flame Spray Process 
To generate bioglass 45S5 microspheres from crushed bioglass 45S5 powder, a flame spray 
approach was used. Flame spraying was carried out using the setup shown in Figure 4-1. 
Bioglass 45S5 powder was fed into the flame gun and sprayed into a collection container 
filled with water to cushion to impact of microspheres. The variables changed during the 
process include the type of gun used and the use of cooling air jets when the Thermospray 
Type 5P gun was used. Controlled variables include the mixture of oxygen to acetylene fuel 
set at 24/29 psi and the length of the gun from the collection container set at twice the 
length of the flame.  
 
 
Figure 4-1: Diagram of flame spray setup. 
Microspheres were collected from the collection container and filtered through a filter 
paper. Once filtered, the microspheres were dried and stored in a desiccator jar until 
microscopy analysis.  
4.2.2.1 Encapsulation of red dye in MS 
To determine whether it is feasible to load antibiotic solution inside hollow microspheres 
and create a hermetic seal around the solution, a brief experiment was conducted. Red dye 
was used as an analogue to antibiotic solution. Red dye would be sprayed into the path of 
the flame at various angles at the highest safe pressure setting available (40kPa). 
Collection Container  
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Microsphere particles were collected in the same manner outline in section 4.2.2 Flame 
Spray Process.  
4.2.3 Characterisation of Microsphere Features 
Microspheres were observed under an optical microscope. Images were taken of whole, 
hollow and chipped microspheres. The optical microscope light setting was set on 
transmissive in order to identify internal features of the microsphere. Other artifacts found 
in the sample were taken. For the encapsulation of red dye in microspheres experiment, 
images of red particles were taken using a reflective optical setting to ensure the red colour 
can be seen. To determine if hollow microspheres were being produced, SEM images were 
taken with the aim of finding broken hollow microspheres.  
4.2.3.1 Particle Size Analysis 
Particle size analysis was conducted on images taken from the optical microscope. 0.1g of 
Bioglass 45S5 or Q-cell microspheres was suspended in 1 mL water or ethanol respectively. 
Three droplets (approximately 0.3 mL) was added to a glass slide and covered with a glass 
covering slip. Three separate images were taken of each sample. Images were chosen to 
ensure that there was at least one microsphere present. Image analysis was conducted using 
parameters which removed particles of less than 2.5 µm diameter. Microspheres which 
overlapped each other were counted as separate entities given that the minimum potential 
microsphere was 2.5 µm in diameter. 
4.2.4 Chemical Etching 
Chemical etching was conducted on Q-cells due to limited supply of Bioglass 45S5. 0.1g of Q-
cell was suspended in 10ml of pure ethanol. 40mL of 0.5M KOH was added to the Q-cell 
suspension. The suspension was heated to 90°C and constantly stirred using a glass rod to 
minimize damage to the Q-cell microspheres. At time intervals 20, 40 and 60 minutes, 
samples of the Q-cell suspension were taken and washed 3 times in distilled water to halt 
any chemical etching reactions. Q-cell samples were analyzed using SEM looking for any 
damage to the surface of the microspheres.  
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4.3 Results 
4.3.1 Optical Images 
4.3.1.1 Flame-Sprayed Bioglass 45S5 Microspheres 
Bioglass 45S5 microspheres were collected from Thermospray Type 5P and a SuperJet S 
flame guns and imaged under an optical microscope. No microsphere morphology 
differences were observed from using the two different guns.  
 
Figure 4-2: Optical images of flame sprayed bioglass 45S5 microspheres. (A) shows the 100x optical view of the 
microspheres collected. (B) shows an example image of whole microspheres found, (C) shows chipped microspheres 
found and (D) shows hollow microspheres found. (B), (C), and (D) type of microspheres were found for both types of 
flame-spray guns. 
Figure 4-2 shows optical images of bioglass 45S5 microspheres collected from the flame 
spray-process. Image A shows a wide frame capture of the microspheres collected. We can 
see a mix of whole, hollow and chipped microspheres of various sizes present in the 
collection. In addition, there is a significant amount of non-microsphere debris present in the 
image. Image B shows an example image of a whole microsphere. Whole microspheres are 
A B 
C D 
62 
 
identified by the gradient grey distribution from the centre to the surface of the microsphere 
and the perfect circular shape of the microsphere. Image C shows an example image of 
chipped microspheres found. Key features of these microspheres are the imperfect non-
circular shape and sharp dark edges through the middle of the microspheres. Cracks can also 
be seen as dark lines running through the microsphere. Image D shows an example image of 
hollow microspheres found. Hollow microspheres are identified by the sharp gradient 
change in the greyscale from the centre to the edge of the microsphere. Hollow 
microspheres also have a perfect circular shape. 
4.3.1.2 Encapsulation of red dye in MS 
Encapsulation of red dye in microspheres was attempted using the protocol listed in section 
4.2.2.1. The product of the experiment was collected and imaged under an optical 
microscope to determine any presence of red dye encapsulated in microspheres.  
 
Figure 4-3: Red dye sample images of red artefacts found. No red microspheres were found. 
A 
B 
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Figure 4-3 shows images of red artefacts found in the red-dye encapsulation microsphere 
collection. Image A shows a red microsphere. It cannot be determined if the red colour lies 
inside a hollow microsphere, evenly distributed throughout a whole microsphere or coated 
on the surface of the microsphere. Image A also highlights the extremely low yield of red 
microspheres found in the collection. Image B shows a red non-microsphere artefact found 
in the collection. Similar other red artefacts were found in the collection at a slightly higher 
yield than red microspheres.  
4.3.2 SEM images 
Bioglass 45S5 microspheres produced by the two types of flame guns were imaged using 
SEM to determine if any surface texture differences were present. SEM images showed that 
there were no surface texture differences between microspheres produced by the two 
different flame guns.  
 
Figure 4-4: SEM images of Bioglass 45S5 microspheres. Top image shows particle size distribution while bottom image 
shows open hollow microsphere. 
Figure 4-4 shows two SEM images of bioglass 45S5 microspheres. The images shows the 
surface of the bioglass 45S5 microspheres is quite smooth. The right image contains what 
appears to be a quarter of a broken hollow microsphere. Closer inspection of the image also 
reveals some hollow pockets at the top right of the broken hollow microsphere.  
4.3.3 Particle Size Analysis 
Figure 4-5 shows the particle size distribution of bioglass 45S5 microspheres produced from 
the two types of flame guns used; Thermospray Type 5P and SuperJet S. In addition, the 
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particle size distribution of Q-cells, which will be used as an analogue for Bioglass 45S5 in 
future experiments, is also compared to the Bioglass 45S5 microspheres. Particle size 
distribution is similar for all three categories. 
 
Figure 4-5: Particle size distribution of Bioglass 45S5 microspheres made from Thermospray and SuperJet flame guns and 
Q-cell microspheres. 
Thermospray particles mostly fall in the 15-20 µm particle size bins at a frequency of 21.20%. 
Microspheres produced using the SuperJet S also frequently fall within the 15-20 µm range 
with a frequency of 25.49%. Q-cell microspheres are generally smaller with falling within the 
10-15 µm range at a frequency of 26.79%.  
4.3.4 Chemical Etching of Q-cells 
Figure 4-6 shows SEM images of Q-cell microspheres which had undergone chemical etching 
treatment over 60 minutes. Comparing the three time point images, there appears to be no 
significant differences in microsphere surface texture over 60 minutes.  
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Figure 4-6: SEM images of chemical etched Q-cell microspheres at time points (A) 20 (B) 40 and (C) 60 minutes. 
4.4 Discussion 
Whole and hollow microspheres were produced using the flame spray process. There was no 
significant difference in microspheres using the Thermospray and SuperJet flame guns. 
During the production process, it was noted that collecting microspheres was much easier 
using the SuperJet gun as opposed to the Thermospray gun. The long narrow barrel and 
shorter flame length of the SuperJet gun reduced the splash of the water in the collection 
container. This ensured that microspheres were not being lost and reduced the likelihood 
and severity of the risks and hazards involved in the process. The use of cooling jets on the 
Thermospray gun significantly increased splash in the collection container. It was deemed 
too hazardous to continue using the cooling jets on the Thermospray gun.  
Optical and SEM images confirm the presence of whole and hollow microspheres. Attempts 
to separate the two types of microspheres proved difficult. Initially, it was predicted that 
hollow microspheres would float in water while whole microspheres would sink. However, 
A B 
C 
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the buoyancy of the hollow microspheres is insufficient for them to float. Having larger 
microspheres with larger internal diameters would most likely allow these hollow 
microspheres to float and be separated from whole microspheres.  
Red dye encapsulation experiments produced very poor yields of red microspheres. The 
extremely low yield made it impossible to verify how the red dye was attached to the 
microsphere whether it is inside, throughout or on the surface of the microsphere. Thus, 
there is insufficient evidence to support that microsphere design iteration 3 is producible 
through the alteration of the flame-spray process.  
Particle size distribution of the Bioglass 45S5 microspheres and Q-cells are similar. Bioglass 
45S5 microspheres produced using both types of flame guns produced microspheres which 
frequently lies in the 15-20 µm range whilst Q-cells mostly fell in the 10-15 µm range. This 
result shows minor differences in particle size. This is important for microsphere attachment 
studies in the following chapter where the size of microspheres would affect the number of 
microspheres able to be attached to scaffolds and the amount of microsphere surface area 
that is bonded to the scaffolds.   
Chemical etching of Q-cells did not show any observable surface roughening after 60 
minutes. It is possible that there was some minor surface texture change on the surface of 
the Q-cell. However, this cannot be confirmed through the SEM images obtained. Chemical 
etching of Q-cells should be performed for over 24 hours for observable surface texture 
roughening. However, it should be noted that Bioglass 45S5 microspheres would react faster 
with alkaline solutions reducing the time required for chemical etching to have an observable 
effect on the surface texture.  
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5 Microsphere Attachment Studies 
5.1 Introduction 
Adherence of bioglass 45S5 microspheres to the scaffold is achieved through a thermal 
attachment process. PCL has a transition phase at 60°C where it becomes a transparent 
mouldable plastic with a sticky surface. By heating the surface of the scaffold until it 
becomes sticky, microspheres can be attached onto the scaffold surface. When the scaffold 
cools and hardens, the microspheres remain attached. 
 
  
 
 
Figure 5-1: Diagram of microsphere attachment to scaffold. As the scaffold is heated to 60°C, the PCL surface begins to 
melt allowing microspheres to sink in. When the PCL cools and hardens, the microspheres become attached. 
Briefly summarizing the relevant manufacturing protocol, bioglass 45S5 powder and scaffold 
are sealed in a package. The package is agitated to disperse the powder throughout the 
scaffold evenly. After agitation, the package is heated inside a preheated oven at 60°C for 20 
minutes, during which the package is rotated to maximise bioglass 45S5 attachment.  After 
heating, excess bioglass 45S5 powder is removed. The scaffold is agitated again to remove 
unattached powder. 
The major issue encountered with this protocol is heat damage to the scaffold. Excessive 
heating of the scaffold will cause it to collapse on itself. The fine struts of the scaffold quickly 
heat up and melt if the temperature is maintained at 60°C for too long. Also, the oven 
Bioglass Microspheres 
Hard/Cold PCL Surface 
Soft/Warm PCL Surface 
T = 60°C T < 60°C T < 60°C 
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currently used is known to fluctuate in temperature although the precise magnitude of 
fluctuation is unknown. 
For this chapter, research will be conducted to characterise the oven currently used and 
evaluate the protocol currently used for bioglass 45S5 attachment to the scaffold. Other 
powder attachment protocols will also be investigated and evaluated against the current 
protocol. From this research, the optimum powder-scaffold attachment protocol will be 
identified and utilised to attach microspheres to the scaffold.  
5.2 Methodologies 
5.2.1 Materials and Equipment 
Scaffolds were produced at the Biomaterials laboratory in the University of Sydney using 
protocols described in previous research by Elizabeth Boughton [181]. Scaffolds were made 
from PCL with dimension of 15mm x 15mm x 10mm and porosity of 95%. Sodium 
borosilicate microspheres were sourced from Barnes (Q-cell 520, Barnes). Medical packaging 
used in experiments was sourced from Medipack AG. Oven characterization and thermo-
attachment studies were conducted using a Pronto oven by Breville. Oven temperature was 
monitored using a digital thermometer (Thermocouple Thermometer, Digitech). 
Microsphere attachment studies were conducted using an Iaxsys™ kit (Iaxsys™, Biometic™) 
capable of actuating scaffolds within 6 well culture plates. Particle counting was conducted 
using a Leica DMRXE upright microscope and Leica Qwin Image Analysis Software. Scanning 
Electron Microscopy was carried out at the Australian Centre for Microscopy and 
Microanalysis (ACMM). 
5.2.2 Oven Characterization Studies 
Characterization studies of the Pronto oven were conducted using a digital thermometer. 
The oven was preheated to 60°C for 30 minutes to ensure that the oven is more temperature 
stable. A K-type thermocouple was sealed in medical packaging and placed in the oven. 
Temperature change was monitored over 10 minutes. 
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5.2.3 Thermo-attachment Studies 
Thermo-attachment studies were carried out using plain scaffolds and scaffolds with Q-cells. 
Scaffolds were sealed in medical packaging with or without 1 gram of Q-cells. Packaged 
scaffolds were placed in the oven that had been pre-heated to 60°C for 30 minutes. Both 
plain scaffolds and Q-cell coated scaffolds were heated for 1, 2, 3, 4, 5 minutes whilst being 
rotated. Q-cell coated scaffolds were cleaned using an air jet to remove excess particles. SEM 
and camera images were taken of both types of scaffolds. Total number of microspheres 
within a scaffold was calculated by counting the number of microspheres in the SEM images, 
determining the microsphere per volume count and using that information to estimate the 
total number of microspheres. The dimensions of the scaffold are on average 15mm x 15mm 
x 8mm. 
5.2.4 Microsphere Attachment Studies 
Q-cell coated scaffolds were produced using a similar protocol mentioned in 5.2.3 Thermo-
attachment Studies. Q-cell coated scaffolds were cleaned using one of two processes; air jet 
particle removal or rinsed in ethanol: water (50:50) solution three times. Scaffolds were then 
placed into a six-well culture plate containing 10mL of ethanol: water (50:50) solution before 
being loaded onto an Iaxsys™ kit. Iaxsys actuation settings were set at 10mm compression 
displacement at 1 Hz for 24 hours. After actuation, 1ml of solution from each well was 
collected. 0.1ml was transferred to a glass slide and the number of microspheres was 
counted under an optical microscope.   
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5.3 Results 
5.3.1 Oven Characterisation Studies 
Temperature fluctuations can have a detrimental effect on the structural integrity of the 
scaffold during thermo-attachment. Minimal temperature fluctuation is ideal for thermo-
attachment of microspheres to the scaffolds leading to more reliable and repeatable 
production protocols. Large temperature fluctuations can lead to scaffold destruction or 
non-adhesion of microspheres to the scaffold.  
 
Figure 5-2: Oven temperature graph after preheating for 30 minutes at 60°C. Average temperature is seen in black. Other 
lines represent individual temperature studies. 
Figure 5-2 shows the temperature change after inserting a thermocouple inside the oven. 
When the oven is opened to place the thermocouple inside, there is a large amount of heat 
lost as seen in the drop in temperature from 60°C to about 23°C at the zero time point. On 
average, the oven reaches 60°C after approximately 4 minutes of insertion. However, there is 
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a large amount of variation in the amount of time it takes for the oven to heat to 60°C and 
temperature fluctuations. The fastest time the oven reached 60°C was after 1 minute and 50 
seconds. Maximum temperature recorded was 68°C and minimum temperature recorded 
after 4 minutes was 54°C.  
5.3.2 Thermo-attachment studies 
Maintaining structural integrity of the scaffold is paramount during thermo-attachment of 
microspheres. Significant reduction in porosity and volume of the scaffold would lead to 
diminished surface area for microsphere attachment and negatively impact the capacity to 
encourage vascularisation throughout the scaffold. 
 
Figure 5-3: Scaffold temperature damage photographs. Images A and B shows plain scaffold temperature damage over 5 
minutes and images C and D shows Q-cell coated scaffold thermal damage over 5 minutes. Time points from left to right 
are 0, 1,2,3,4 and 5 minutes.  
Figure 5-3 shows the heat damage to plain scaffolds and Q-cell coated scaffolds over 5 
minutes. Plain scaffolds are damaged significantly over 5 minutes as seen in images A and B. 
By 5 minutes, the height of the scaffold has decreased by approximately 80%. In addition, 
A 
B
  
 
C
 
D 
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the porosity of the plain scaffolds was severely compromised. In comparison, Q-cell coated 
scaffolds had less thermal damage. By 5 minutes, Q-cells coated scaffolds had a height 
reduction of approximately 50%. Porosity was not visibly affected.  
Figure 5-4 shows SEM images of plain scaffolds with and without thermal damage. Image A 
shows the SEM of undamaged plain scaffolds where the scaffold has fine struts and high 
porosity. The struts in these images fall in the range of 20-200 µm. In contrast, image B 
shows a thermal damaged scaffold. The struts in this image are thicker than the struts in 
image A lying in the range of 50-600 µm. In addition, the scaffolds are less porous in image B 
than in image A.  
 
 
Figure 5-4: SEM images of (A) plain scaffold and (B) heat damaged plain scaffold after 5 minutes 
Figure 5-5 shows SEM images of microsphere attachment studies. Image A shows a scaffold 
with a confluent coating of Q-cells after being heated for 5 minutes. The scaffold is still 
porous although the extent at which porosity has been compromised is unknown. Image B 
A 
B 
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shows a scaffold that has been heated for 4 minutes with moderate coating of microspheres. 
The scaffold surface also contains deformations where microspheres have fallen off during 
the cleaning process. Image C shows a scaffold that had been heated for 3 minutes. There 
are a few microspheres attached to the scaffold. In addition, there are no obvious 
deformations on the scaffold surface to suggest that the scaffold was sufficiently heated to 
create an adhesive surface for microspheres to attach to. Porosity of this scaffold appears to 
be unchanged. 
 
 
Figure 5-5: Microsphere attachment studies. Scaffolds were heated with Q-cells for (A) 5 minutes, (B) 4 minutes and (C) 3 
minutes. 
Table 5-1 calculates the total number of microspheres in each scaffold based on the number 
of microspheres seen in each image and for a standard scaffold with dimensions 15mm x 
15mm x 8mm. Estimated total number of microsphere attached to scaffolds differed by 
orders of magnitude between each heating protocol. The scaffold in SEM image A has an 
A B
   
C 
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estimated 1.45 x 109 microspheres, SEM image B has an estimated 3.09 x 108 microspheres 
and SEM image C has an estimated 3.66 x 107 microspheres.  
Table 5-1: Microsphere counts per scaffold based on SEM images as seen in Figure 5-5. 
SEM Image 
Scaffold 
Total MS 
count in SEM 
image 
Field Area 
(µm2) 
MS count per 
cm3 
(assuming depth 
is 200µm) 
Estimated 
number of MS in 
scaffold (Volume 
of scaffold = 
1912.5cm3) 
A 1030 6.776 x 106 7.6 x 105  1.45 x 109 
B 135 4.18 x 106 1.61 x 105 3.09 x 108 
C 16 4.18 x 106 1.91 x 104 3.66 x 107 
 
 
 
 
 
 
 
Table 5-2 shows the particle counts for Q-cell coated scaffolds that had been cleaned using an 
air jet or washed in 50:50 ethanol: water solution and actuated over 24 hours in an Iaxsys kit. 
An average, Q-cell coated scaffolds cleaned using the air jet had fewer particles released 
compared to Q-cell coated scaffolds cleaned with ethanol: water solution. On average, air jet 
cleaned scaffolds released approximately 15,333 microspheres or (1.06 x 10-3) % of total 
microspheres attached to the scaffold. Scaffold washed with ethanol: water solution 
released 40,667 microspheres or 2.80 x 10-3 % of total attached microspheres. 
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Table 5-2: Particle count for microsphere attachment study 
Scaffold 
Cleaning 
method 
Total Image 
Count 
Count/mL 
Total MS 
released 
% MS released 
Air jet 1 230.00 2,300.00 23,000.00 1.59E-03 
Air jet 2 100.00 1,000.00 10,000.00 6.90E-04 
Air jet 3 130.00 1,300.00 13,000.00 8.97E-04 
 
AIR JET 
AVERAGE 
 
153.33 1,533.33 15,333.33 1.06E-03 
Washed 1 760.00 7,600.00 76,000.00 5.24E-03 
Washed 2 160.00 1,600.00 16,000.00 1.10E-03 
Washed 3 300.00 3,000.00 30,000.00 2.07E-03 
 
WASHED 
AVERAGE 
 
406.67 4,066.67 40,666.67 2.80E-03 
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5.4 Discussion 
In this chapter, studies were carried out to determine the optimal method of attaching 
microspheres to scaffolds.  
Results from the oven temperature experiments seen in Figure 5-2 show that some 
fluctuation in temperature. Temperature fluctuation ranges from 54-67°C. There were also 
significant differences in the time it took the oven to reach 60°C. Minimum time taken to 
reach 60°C was 2m 40s. There was a potential to significantly damage and deform the 
scaffold. Images in Figure 5-3 and Figure 5-4 show how excessive heating can damage plain 
scaffolds reducing height and porosity, and increasing the thicknesses of struts. The 
reduction in scaffold volume is not ideal in treating large and deep chronic wounds. In 
addition, the reduction in scaffold porosity could interfere with the vascularisation of the 
scaffold. 
On the contrary, scaffolds that had been coated with microspheres appeared to be less 
damaged by excessive heating as seen in Figure 5-3 and Figure 5-5.  In order to achieve a 
confluent coating of microspheres onto the scaffold surface, scaffolds should ideally be 
heated for 5 minutes. From Table 5-1, the maximum number of microspheres which can be 
attached to a standard size scaffold (15mm x 15mm x 8mm) is 1.45 x 109. To be able to 
attach the maximum amount of microspheres whilst minimising scaffold damage is of great 
benefit. Not only does it reduce heat damage to the scaffold, it also increases the potential 
drug loading capacity of the scaffold.  
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Table 5-2 shows the number of microspheres which are lost after the scaffold is actuated for 
24 hours with a 10mm compression, and after cleaning using an air jet or ethanol: water 
solution. Scaffolds cleaning using an air jet released the lowest amount at 15,333 
microspheres or 1.06 x 10-3% of total microspheres attached while scaffolds washed with 
ethanol: water solution released 40,667 microspheres or 2.8 x 10-3%.  It is hypothesized that 
less microspheres were released from air jet cleaned scaffolds due to the high shear forces 
which dislodged weakly bonded microsphere. Minimal microsphere loss is beneficial to 
maintain localised drug delivery.  
Ideal microsphere attachment to scaffolds can be achieved by saturating the scaffold with 
microspheres, heating the scaffold at 60°C for 5 minutes and removing excess microspheres 
using an air jet. Microspheres attached using these methods are firmly secured with minimal 
microsphere loss during cyclical loading.  
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6 Drug Release Studies 
6.1 Introduction 
This chapter will investigate the potential of scaffolds and ceramic glass microspheres as 
delivery vectors for drugs, primarily antibiotics. Experiments in this chapter aim to verify the 
capability of the two part device to deliver antibiotics and to maintain a sustained drug 
delivery.  
One of the key aspects investigated in this chapter is drug loading efficiency. Drug loading 
efficiency refers to the percentage of drug mass per unit mass of delivery vector, typically 
expressed as %w/w. This is different to entrapment efficiency which compares the mass of 
drug loaded to the total mass of drug available for loading. There are a number of methods 
which can be used to determine the amount of drug loaded onto delivery vectors. The most 
common method used is measuring the total amount of drug released using various 
detection methods. A key limitation of this method is that total amount of drug released is 
not necessarily similar to the total amount of drug loaded. When using this method, it is 
important to understand how the drug in entrapped on the delivery vector and the release 
kinetics most likely associated with the vector. For this chapter, where antibiotics are 
primarily attached to the immediate surface of the vectors, it is reasonable to deduce that 
the difference between total drug released and total drug loaded is negligible as there is no 
other type of bonding between the antibiotic and the delivery vector which would 
significantly affect the differences. 
Another key aspect investigated in this chapter is the drug elution profile. A logarithmic 
elution profile is expected due to the non-complex method of antibiotic loading. Features of 
the elution profile which will be analyzed are the rate of release and time length of the burst 
phase and sustained phase, and total amount of antibiotic released which will be defined at 
maximum value recorded where neighboring time point values are less than 5% different. 
These features are important as they affect the capabilities of the device to act as a long-
term antimicrobial skin scaffold.  
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In addition, the concentration of antibiotic released will be calibrated to reflect unit mass of 
delivery vector used. From this unit of measurement, sample iterations can be compared to 
reflect drug loading efficiency. 
6.2 Methodology 
6.2.1 Materials and Equipment 
Chloramphenicol antibiotic powder, pure ethanol and potassium hydroxide were sourced 
from Sigma Aldrich. Chloramphenicol was used as the analogue drug to be loaded onto 
delivery vectors although any drug would have sufficed.  Scaffolds were produced in the 
Biomaterials laboratory in the University of Sydney according to protocols designed by 
Elizabeth Boughton to the dimension of 1.5mm x 5mm x 10mm with 95% porosity [181]. Q-
cells were sourced from Barnes. Equipment used in the following experiments includes a 
vibroslicer (752M Vibroslice, Campden Instruments) and a UV-visible spectrophotometer 
(UV-1601, Shimadzu).  
6.2.2 Chloramphenicol Antibiotic Stock Solution 
A stock solution of chloramphenicol was produced at a concentration of 100mg/ml. 1g of 
chloramphenicol powder was dissolved in 10ml of pure ethanol and mixed thoroughly to 
ensure complete dissolution. Further concentrations of chloramphenicol solutions used in 
this chapter were produced through dilution of the stock solution in pure ethanol. All 
solutions of chloramphenicol were stored at 4°C when not in use.  
6.2.3 Chloramphenicol Loading onto Vectors 
Two methods were used to load chloramphenicol onto the delivery vectors; soaking and 
infusion. The primary method to be tested is soaking the delivery vector in antibiotic 
solution. The method of infusing the antibiotic is also experimented as this method is most 
commonly used in literature. 
6.2.3.1 Soaking 
Scaffolds (1.5mm x 5mm x 10mm), Q-cell microspheres and chemically etched Q-cell 
microspheres where soaked in a 10mg/ml chloramphenicol solution for 24 hours. After the 
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soaking period, scaffolds were removed and air dried on an absorbent cloth in a chemical 
fume hood. Once dried, the mass of the scaffolds was measured and compared with the pre-
loading mass. Microspheres were separated from remaining chloramphenicol solution and 
attached to unloaded scaffolds using thermal adhesion. Mass before and after loading were 
recorded and compared.  
6.2.3.2 Infusion 
Scaffolds were infused with chloramphenicol by adding chloramphenicol powder to the 
manufacturing process. Briefly summarizing, chloramphenicol powder was added to the 
polymer solution to a concentration of 10mg/ml. The scaffolds were processed per standard 
manufacturing protocols. Scaffolds were cut into 1.5mm x 5mm x 10mm slices using a 
vibroslicer. Mass measurements of scaffolds were taken after loading.  
6.2.4 Absorbance Spectrum 
The absorbance spectrum of chloramphenicol was determined using the Absorbance 
program on the spectrophotometer. Briefly summarizing, the program measures the 
absorbance of the test solution over a range of wavelengths and returns a graph as seen in 
Figure 6-1. A 50µg/ml solution of chloramphenicol in distilled water was prepared and 
transferred into a quartz cuvette. The cuvette containing the chloramphenicol solution was 
placed in the spectrophotometer and analyzed using the Absorbance program. From the 
graph, an ideal wavelength can be determined for which absorbance spectrum analysis with 
chloramphenicol solution will be used.    
6.2.5 Calibration 
Using the best absorbance wavelength determined in 6.2.4 Absorbance Spectrum, a 
calibration curve can be produced at that wavelength. Chloramphenicol solutions of 
100µg/ml, 50µg/ml, 25µg/ml, 12.5µg/ml and 6.25µg/ml were analyzed and their respective 
absorbance recorded. A graph of absorbance against concentration and trend line through 
(0, 0) was plotted. From the calibration curve, the absorbance coefficient can be determined 
using the equation; 
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Where A is the absorbance, ε is the absorbance coefficient, c is the concentration of the 
sample and l is the length of cuvette set at 1cm.  
6.2.6 Drug Release 
The sample iterations used in drug release studies were scaffolds soaked in chloramphenicol 
solution (positive control), plain scaffolds (negative control), scaffolds with intact 
microspheres loaded with CAP, scaffolds with chemically etched microspheres loaded with 
chloramphenicol and scaffolds infused with CAP. Triplicates of each sample iteration were 
produced to provide a method for measuring reliability through calculation of the standard 
deviation. 
Each sample was placed in 5ml of PBS solution. Before each sampling time point, all the 
samples and solutions were shaken manually to ensure even distribution of solution and 
restore any chloramphenicol molecules electrostatically bound to the vial walls to solution. 
At time points 0, 10 min, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, 3 days and 7 
days, 200µl of sample fluid was transferred into 800µl of PBS diluting the original sample by a 
factor of 5. The absorbance of each diluted sample solution was measured and recorded. 
Results were calibrated taking into account the dilution factor, amount of antibiotic removed 
during each sampling and the mass of the delivery vector.  
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6.3 Results 
6.3.1 Absorbance Spectrum 
 
Figure 6-1: Absorbance spectrum of chloramphenicol from 200nm to 400nm wavelengths. 
Figure 6-1 shows the absorbance spectrum of chloramphenicol from 200 to 400nm. There 
are two peaks within this range, one at approximately 205nm and another at 278nm. Whilst 
the peak at 205nm records a stronger absorbance than the peak at 278nm, it lies on the 
extremity of the spectrophotometer capabilities thus potentially causing errors. The peak at 
278nm records a sufficiently strong absorbance close to 1 and is well defined locally. Further 
experiments were conducted using an absorbance wavelength of 280nm which corresponds 
to wavelengths other researchers have used to detect chloramphenicol [190, 191].  
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6.3.2 Calibration 
 
Figure 6-2: Calibration curve of chloramphenicol at 280nm. 
The calibration curve shown in Figure 6-2 shows a strong direct linear relationship between 
absorbance and concentration of chloramphenicol at 280nm. The trend line has a strong 
correlation coefficient with an R2 value of 0.9973. From the trend line equation, we can 
determine that the absorbance coefficient ε is 0.0297. The equation relating absorbance to 
concentration is as follows; 
Equation 2: Absorbance equation 
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6.3.3 Drug Release 
 
Figure 6-3: Mass of chloramphenicol released in µg over 4 hours. 
 
Figure 6-4: Mass of chloramphenicol released in µg over 7 days 
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Figure 6-3 and Figure 6-4 show the mass of chloramphenicol released over 4 hours and 7 
days respectively. Figure 6-3 shows that over a period of 4 hours, the positive control had the 
largest amount of chloramphenicol released at 49.8 µg. This was followed by infused 
scaffolds (42.6 µg), intact microspheres (39.0 µg), chemically etched microspheres (28.7 µg) 
and negative control scaffolds (1.9 µg). The burst phase appears to be over by 2 hours for the 
positive control and intact microspheres. The burst phase of chemically etched microspheres 
lasts for 1 hour before the rate of release slows significantly. The burst phase for infused 
scaffolds does not appear to be over by 4 hours according to Figure 6-3.  
Figure 6-4 shows that the burst phase for the positive control and infused scaffolds lasts 
slightly longer than a day. For each of the scaffold iterations, there is no noticeable increase 
in chloramphenicol release during the sustained phase. The maximum release recorded 
belonged to positive control scaffolds with 61.3 µg. This was closely followed by infused 
scaffolds with a maximum recorded release of 60.4 µg. Intact microspheres had a maximum 
release of 39.2 µg and chemical etched microspheres had a maximum release of 28.7 µg. 
Negative control scaffolds showed minor fluctuations in absorbance values averaging close 
to zero for both figures.  
Both graphs show relatively large standard deviations for all sample iterations with exception 
to negative control scaffolds. The highest standard deviation recorded was 17.9 for intact 
microspheres at the 2 hour time point. Other maximum standard deviation values recorded 
include 4.7 for positive control scaffolds, 14.7 for chemical etched microspheres, 11.6 for 
infused scaffolds and 2.8 for negative control scaffolds.  
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Figure 6-5: Release profile over 4 hours. Burst phase is typically over by 2 hours. Data calibrated to express 
chloramphenicol concentration release per milligram of delivery vector. 
 
 
Figure 6-6: Release profile over 7 days. . Data calibrated to express chloramphenicol concentration release per milligram 
of delivery vector. 
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Figure 6-5 and Figure 6-6 show the same results as Figure 6-3 and Figure 6-4 but calibrated to 
show the mass of chloramphenicol released per milligram of delivery vector (µg/mg). Intact 
microspheres contained the largest amount of chloramphenicol per gram of delivery vector 
followed by chemically etched microspheres, positive control scaffolds, infused scaffolds and 
negative control scaffolds. Maximum release per gram of delivery vector for intact 
microspheres was 40.5 µg/mg followed by chemically etched microspheres (15.4 µg/mg), 
positive control scaffolds (2.7 µg/mg), infused scaffolds (1.8 µg/mg) and negative control 
scaffolds (0.07 µg/mg). Burst phase and sustained phase time points remain the same.  
Standard deviations are much lower compared to standard deviations in Figure 6-3 and 
Figure 6-4. Maximum standard deviations for intact microspheres were 5.9 followed by 
chemically etched microspheres (2.9), infused scaffolds (1.76), positive control scaffolds 
(0.18) and negative control scaffolds (0.07).  
6.4 Discussion 
As mentioned in section 6.1 Introduction, drug loading efficiency is one of the key criteria’s in 
assessing viabilities of various drug delivery vectors. Whist direct measurement of drug 
loading efficiencies was not possible; the efficiency of each delivery vector can be 
extrapolated from total drug release per unit mass of delivery vector within reasonable 
values.  
Per unit mass of delivery vector, intact microspheres had the highest loading efficiency of the 
delivery vectors tested. This is expected as there is a high surface area to volume of spheres 
compared to other 3D structures. This allows for more antibiotics to bind to the 
microspheres by weak electrostatic bonds. Microspheres which were chemically etched had 
the second highest drug loading efficiency.  
Chemically etched microspheres had a much lower drug loading efficiency compared to 
intact microspheres. At maximum values, chemically etched microspheres had a 62% lower 
loading efficiency than intact microspheres. While chemically etched surfaces should ideally 
have a higher available surface area, results from section 4.3.4 
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Chemical Etching of Q-cells showed that there was little to no observable change in surface 
texture. In addition, residual alkaline products may have interacted with antibiotic molecules 
causing them to degrade even after extensive washing.  
Positive control scaffolds and infused scaffolds had the lowest drug loading efficiencies at 2.7 
µg/mg and 1.8 µg/mg respectively. Positive control scaffolds would have a higher loading 
efficiency due to antibiotic molecules binding to the surface of the scaffold. In contrast, while 
infused scaffolds had antibiotic loaded into the polymer, most of the antibiotic loaded near 
the surface of the scaffold was removed during the scaffold processing.  
Whilst microsphere-centered designs have better drug loading efficiencies, it should be 
noted that total antibiotic released from scaffolds coated in microspheres are much lower 
when compared to scaffolds loaded with  antibiotics as seen in Figure 6-3 and Figure 6-4. 
Positive control scaffolds and infused scaffolds had a maximum drug release of 61.3 µg and 
60.4 µg respectively. Intact and chemically etched microspheres had a lower maximum drug 
release of 39.2 µg and 28.7 µg respectively. Microsphere-centred designs had lower 
maximum drug release as there was much less microspheres attached to the scaffold when 
compared to antibiotic-loaded scaffolds in terms of mass. In addition, antibiotic-loaded 
scaffolds had a longer antibiotic burst phase of 1 day compared to microsphere-coated 
scaffolds which had a burst phase lasting 1 hour or less. A prolonged release of antibiotics is 
desired to maintain antimicrobial effects.  
There is a significant deviation in the release of chloramphenicol for all the delivery vector 
iterations. The high standard deviations would most likely be issues in manufacturing 
regarding the reproducibility and reliability of the product. The cause for the high standard 
deviations in total drug released is most likely due to the non-conformity of the scaffold 
porosity and subsequently surface area. This would greatly affect the amount of drug and 
microspheres that can be loaded onto the scaffold. Further repetition of the experiment may 
yield more concise loading efficiency data which could be extrapolated to estimate the total 
drug loading.  
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7 General Discussion 
In section 3.4 Experimental Philosophy, Table 3-7 outlined the relevant experiments that 
would be carried out and the relevant user requirements and design risks associated with 
each experiment. Table 7-1 shows the completed version with pass/fail/incomplete results 
filled in.  
Table 7-1: Completed experiment table 
# Experiments Relevant UINs Pass/Fail/ Incomplete 
 Chapter 4 - Production and Characterisation of Microspheres 
4.1 Production of Bioglass 45S5 microspheres 
UR3,UR4, UR9, 
RA4 
Pass 
4.1a  Whole Pass 
4.1b  Hollow Pass 
4.1c  Porous Incomplete 
4.2 Able to load antibiotics within hollow microspheres UR3, UR4 Fail 
4.3 Standardize particle size UR3, UR9 Pass 
 Chapter 5 - Microsphere Attachment Studies 
5.1 Able to attach microspheres to scaffold UR2, UR3, RA5 Pass 
5.2 Maintain scaffold integrity during attachment process UR7, RA5, RA6 Pass 
5.3 Maintain scaffold integrity during cyclic loading test UR7, RA9 Pass 
 Chapter  6 - Drug Release Studies 
6.1 Able to load antibiotics onto microspheres 
UR3, RA7, RA8 
Pass 
  Able to load antibiotic-loaded microspheres onto scaffolds Pass 
6.2 Release of antibiotic from device 
UR4, RA8 
Pass 
6.2a  1 day Fail 
6.2b  1 week Fail 
6.3 Reliable release of antibiotics from device UR3, UR4 Fail 
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Chapter 4 investigated the production of whole, hollow and porous microspheres using 
flame spraying and chemical etching techniques, the potential to load antibiotics inside a 
hermetic sealed hollowed microsphere and the particle size distribution of microspheres 
produced. Whole and hollow microspheres were produced in the same batch using a flame 
spray technique. These microspheres mostly fell within the 15-20 µm size. Production time 
for the flame spray technique did not exceed one hour including set-up time. Attempts were 
made to separate the whole and hollow microspheres using buoyancy differences but were 
unsuccessful due to the negligible differences.  
Attempts at creating a hollow microsphere filled with fluid were not successful. Red dye, 
which was used as an analogue for antibiotic solutions, was detected in very minute amounts 
often on irregularly shaped particles. While it may be impossible to load antibiotic solutions 
inside hermetically sealed microspheres using flame spray techniques, the production of 
hollow microspheres allow for alternative drug loading avenues to be considered.  
Creation of porous microspheres was conducted on sodium borosilicate microspheres 
instead of bioglass 45S5 microspheres due to supply constraints of bioglass 45S5. Over a one 
hour period, no observable etching of the microsphere surface was found on SEM imaging. It 
should be noted that Bioglass 45S5 would react faster to alkaline solutions reducing the time 
required for chemical etching to have an observable effect on surface texture [192].  
Whilst outcomes 4.1c and 4.2 were not achieved, all other outcomes set for the chapter 
passed. The outcomes which were not achieved do not prevent the development of a two 
part synthetic skin scaffold with antimicrobial properties.  
Experiments conducted in chapter 5 investigated the attachment of microspheres to 
scaffolds whilst maintaining scaffold integrity. In addition, the mechanical stability of the 
device was tested under a cyclic loading test with parameters of 50% compression, 1 Hz cycle 
for 24 hours.  
 Microspheres were able to be attached to the scaffold with minimal damage. Scaffolds were 
heated together with microspheres at 60° for 5 minutes whilst being constantly rotated to 
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maximize microsphere attachment. This protocol takes advantage of the low glass transition 
phase of PCL and the structural support confluent coatings of microspheres which prevent 
complete scaffold collapse. Using this protocol, approximately 1.45 x 109 microspheres were 
attached to the scaffold. During cyclic loading tests, 15,333 microspheres or 1.06 x 10-3% of 
microspheres were displaced from the scaffold.  
These results satisfy the user requirements and design risks linked to the experiments. 
Results from this chapter validate the capability for two separate products to be successfully 
combined to act as a single device. 
Loading of antibiotics and their subsequent release form microspheres attached to scaffolds 
were explored in Chapter 6. Chloramphenicol antibiotic was successfully loaded onto 
microspheres. Microspheres coated scaffolds had a higher drug loading efficiency compared 
to scaffolds infused with chloramphenicol. However, total chloramphenicol release was 
higher for infused scaffolds compared to microsphere coated scaffolds. This is due to the 
greater volume and surface area of the scaffold compared to microspheres. Burst phase of 
microsphere coated scaffolds lasted for 1 hour compared to infused scaffolds which lasted 1 
day.  
Overall, while the device was able to load and release antibiotics, more design modifications 
may be required to create a sustained antimicrobial device. Nevertheless, the device can be 
used as a wound healing device with local delivery of antibiotics directly to the infection site.  
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8 Conclusions  
The core aim of this thesis was the development of a two-part synthetic skin scaffold 
consisting of bioactive glass microspheres and a biocompatible biodegradable 3D porous 
scaffold. The thesis looked at three parts of the development; production of hollow Bioglass 
45S5 microspheres, attachment of microspheres to 3D porous scaffolds using non-
destructive methods and loading and release of drugs such as antibiotics from the device. 
Main finidings of this thesis are summarized below.  
• Bioglass 45S5 microspheres can be produced from Bioglass 45S5 powder using a 
flame spray technique. Microspheres produced this way were whole or hollow. 
• Liquid solutions were unable to be loaded inside hermetically sealed microspheres 
during the flame spray process.  
• Resultant microspheres were mostly 10-15 µm in size which is ideal for attachment to 
scaffolds. 
• Microspheres could be attached to PCL scaffolds using a thermal attachment process. 
• Scaffold integrity was not compromised during microsphere attachment. 
• Minimal loss of microspheres occurred during cyclic mechanical actuation. 
• Antibiotics could be loaded onto the surface of microspheres.  
• Subsequent release of antibiotics from microsphere coated scaffolds lasted for 1 
hour. 
• Release of antibiotics from scaffolds infused with antibiotic lasted for 1 day. 
• There was a wide variation in total antibiotic release due to variables in microspheres 
attached and surface area of scaffolds.  
• A two part chronic skin wound healing device with antimicrobial activity could be 
constructed from polyester scaffolds and bioactive glass microspheres. Antibiotics 
could be delivered locally to the wound site using this device. 
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9 Future Recommendations 
This thesis was able to develop hollow Bioglass 45S5 microspheres, thermoattach 
microspheres to a 3D porous scaffold and load and deliver antibiotics from the two part 
device. Further areas for future investigations are listed below. 
• Modifications to hollow microspheres to include a hollow porous design to increase 
surface area and bonding sites for antibiotics. Continuing on, these modified 
microspheres could be coated in a biocompatible polymer to help delay and create a 
sustained antibiotic release. This could form the basis of a follow-up Masters or PhD 
project.  
• There is a potential for antibiotic loaded microspheres to be used in conjunction with 
biological skin grafts provided that there is sufficient penetration of the microsphere 
within the graft to provide an antimicrobial environment through the graft. This 
would require a method of inserting microspheres evenly through a graft. Burst and 
sustained release of antibiotics would be a major requirement. If successful, other 
drugs or biologically active proteins could be loaded to encourage vascularization 
throughout the graft.  
• Microbiological and animal studies should be carried out once a solution has been 
created for sustained antimicrobial activity. Microbiological tests should be carried 
out against a range of microorganisms such as staphylococcus aureus, pseudomonas 
aeruginosa and other bacterial and fungal strains. 
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11 Appendix 
11.1 Appendix A – Protocols 
11.1.1 Chapter 4 Production and Characterisation of Microspheres 
 
Flame Spray Protocol 
Aim 
Production of Bioglass 45S5 microspheres 
Equipment 
• Bioglass 45S5 powder (<40µm) 
• Flame guns: Thermospray Type 5P (Metco), SuperJet S (Eutalloy) 
• Paint spray gun (Metabo) 
• Red dye 
• Steel collection container 
• Filter paper (>50cm diameter) 
• Funnel 
Safety 
• Tinted glassed 
• Flame guns to be operated by trained personnel 
Method 
1. Load bioglass 45S5 powder into dispensing container and attach to flame gun. Fill 
steel collection container with 1-2cm of water.  
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2. Ignite flame gun and set acetylene/oxygen pressures to 34/34 psi. Following this set 
air jet pressure to 500kPa if needed. If red dye is required, set paint sprays gun 
pressure to 40kPa. 
3. Aim flame path towards to steel collection container whilst maintaining 
approximately 20-40cm distance to bottom of container. Be aware of splash back and 
compensate accordingly. If paint spray gun is also being used, point towards the 
bottom of container whilst crossing flame spray gun. Be careful of steam generation. 
4. Engage powder dispenser and collect bioglass 45S5 microspheres in container.  
5. Disengage powder dispenser and turn of acetylene/oxygen fuel. 
6. Filter the microsphere containing water and dry the filter paper. Store filter paper in 
plastic bag for analysis.  
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Chemical Etching of Q-cells (Sodium Borosilicate microspheres) 
Aim 
This experiment protocol aims to produce porous hollow microspheres through chemical 
etching techniques using Potassium Hydroxide (KOH) solutions. 
Equipment 
• Q-Cell 
• KOH pellets (85% ACS) 
• Distilled water/demineralized water or pure ethanol 
• Heating stove with magnetic stirring 
• Filter paper. 
• Glass funnel 
• Fume hood 
• 10 ml containers (preferably plastic). 
Safety Precautions 
• Fume hood 
• Safety goggles 
• Gloves 
• Lab coat 
Hazards 
KOH solution is corrosive. Avoid physical contact and inhalation of fumes. Always wear the 
personal protective equipment and use the fume hood to conduct the experiment. 
Methodology/Protocol 
1. Make a stock solution of 0.5M KOH and store in plastic container. The molar mass of 
KOH is 56.1056 g/mol. Therefore 28.0528g of KOH in 1L for a 0.5M solution. Use 
ethanol if we have enough. If not, use demineralized water or ratio as determined by 
your previous results.  
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a. NOTE: THERE IS ONLY 26g of 85% KOH LEFT 
i. Effective KOH left = 22.1g 
1. Therefore 0.3939 moles left 
a. Therefore a 0.5M solution needs 26g of KOH in 787.8ml 
of solvent 
b. 16.5g of KOH in 500mL of solvent 
c. MAKE SURE YOU SLOWLY ADD PELLETS TO WATER, 
NOT THE OTHER WAY ROUND!!!!!!!!!!! 
2. Before adding stock solution to Q-cells, heat solution to 90°C in a fume hood (Allow 
30mins or so. Use a water bath setup. 
a. If you are using ethanol, reduce heat to 50°C or the ethanol will boil. 
3. In six separate containers, add 0.1g of q-cell. In each container, add 5ml of KOH stock 
solution. 
4. Maintain temperature at 90°C and stir or agitate slowly. 
5. Samples should be taken at relevant intervals. 
6. Filter microspheres out using filter paper and immediately wash with de-mineralized 
water.  
a. If filter paper breaks, add 90ml of water to reduce the strength of the base 
and filter again. Repeat if necessary. 
7. Dry filter paper in 60°C oven in S197 lab. Do not forget to label them. 
8. Take microscope shots. Leave some for scanning electron microscopy. 
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11.1.2 Chapter 5 Microsphere Attachment Studies 
 
Oven Characterisation 
Aim 
Observe the temperature fluctuations of the Pronto Oven 
Equipment 
• Pronto Oven + Package attachment 
• Digital Thermometer and K-Type sensor (Digitech) 
• Medipack Packaging 
• Heat Sealer 
Method 
1. Insert the K-Type sensor in the medipack packaging and seal using the heat sealer. 
2. Pre heat the oven to 60°C. 
3. Attach the package to the package attachment and insert inside the oven 
4. Record temperature every 10s for 5-10 minutes.  
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Thermo-attachment studies 
Aim 
Determine if thermoattachment process damages the scaffold. 
Equipment 
• Polycaprolactone scaffolds 
• Pronto oven 
• Medipack packaging 
• Q-cell/Sodium Borosilicate microspheres 
Method 
1. Place scaffold in medipack packaging with Q-cells. Seal the package 
2. Preheat the oven to 60°C. 
3. Insert package in oven and set rotating option on. 
4. Heat the package for 1,2,3,4 or 5 minutes. 
5. Remove package and retrieve scaffolds. Remove excess q-cells using air jet blasts. 
6. Repeat for plain scaffolds. 
7. Take optical and SEM images. 
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Microsphere attachment studies 
Aim 
Determine microsphere loss during cyclic loading 
Equipment 
• Scaffolds coated with Q-cells 
• Iaxsys kit and well inserts 
• 6 well culture plate 
• Ethanol: water solution (50:50) 
Method 
1. Attach scaffolds to well inserts using adhesive glue and place in culture plate 
2. Fill wells with 10 ml of ethanol: water solution. Close culture plate. 
3. Place culture plate onto Iaxsys kit. 
4. Set settings to 10mm compression displacement, 1Hz frequency and 24 hour 
duration. 
5. Start machine. 
6. Once finished, agitate solutions in wells to ensure even distribution of unattached Q-
cells. 
7. Pipette 1ml of solution into Eppendorf tubes and label accordingly. Use 0.1ml of 
solution when preparing glass slide for optical counts. 
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11.1.3 Chapter 6 Drug Release Studies 
 
Spectrophotometry protocol 
Introduction 
As part of research and development into synthetic polyester skin scaffolds, we are investigating the 
potential of sustained controlled drug delivery using bioactive glass microsphere vehicles loaded 
using novel methods. 
Equipment required 
Chloramphenicol stock solution (100mg/ml) 
Spectrophotometer 
Quartz cuvette 
Phosphate Buffered Solution (PBS) 
Drug-loaded microspheres 
Protocol 
The experiment protocol will be divided into 3 broad aspects 
Determine Absorbance and Calibration curve 
The wavelength where maximum absorption occurs is required to ensure the highest sensitivity of 
the spectrophotometer. Chloramphenicol has a max absorption peak at 280nm. In order to create 
our own absorbance spectrum graph, a 100 µl/ml sample will be used to test absorbance from 200 to 
350nm at 10nm intervals.  
Given an antibiotic stock solution, a concentration curve is required for determining drug loading and 
release from the carriers. From the stock solution (100mg/ml), 1ml samples of concentrations 5, 10, 
20, 50, 100 µl/ml will be prepared. The absorbance at the max absorption wavelength of each sample 
will be recorded and used to create a graph with a linear correlation which should fit the equation: 
 
Where A = Absorbance 
 ε = calibration factor 
 c = concentration of sample 
 l = length of cuvette (normally 1cm) 
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Determine Loading Efficiency 
Drug loading efficiency will be determined by measuring the antibiotic concentration in the soaking 
solution before and after drug loading over microspheres. Microsphere samples will be soaked in 
10mg/ml antibiotic solution over 24 hours to load antibiotics. Loading efficiency is determined by: 
 
Mass of antibiotic loaded onto microspheres per gram of microspheres will also be calculated. 
 
This will be used to determine how much drug loaded microspheres is required to produce 
absorbance readings for drug elution tests. 
Determine Drug Elution 
After antibiotic loading, the loaded microspheres will be rinsed in water to remove excess antibiotic 
not bound to the microspheres. The rinsed water will be collected and tested for antibiotics to 
determine potential loss in loading efficiency. 
Loaded microspheres will be tested for drug releasing kinetics over a period of 24 hours. A standard 
amount of microspheres will be placed in 5 ml of PBS and continuously shaken for the duration of the 
experiment. The amount of microspheres to be placed in each testing jar is determined as follows: 
  
This equation is designed to give a max absorbance reading of 1.  
Samples from each testing jar will be taken at time points 0, 10 min, 30 min, 1 hr, 1.5 hr, 2 hr, 4hr, 8 
hr and 24 hrs. Tests will be conducted in triplicates.  
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11.2 Results 
11.2.1 Chapter 4 Microspheres Results 
Bioglass 45S5 microspheres and Q-cell Particle size analysis 
Thermospray 
      Bin 
   
Lengt
h 
 
    
Count 
    
Count 
      
Bin 
   
Length 
 
    
Count 
    
Count 
      
Bin 
   
Length 
 
    
Count 
    
Count 
          
     
(µm) 
 
             (%)           
     
(µm) 
 
             (%)           
     
(µm) 
 
             (%) 
1 0-5  0 0 1 0-5  6 8.7 1 0-5  6 4.35 
2 5-10  26 23.85 2 5-10  4 5.8 2 5-10  18 13.04 
3 10-15  24 22.02 3 10-15  12 17.39 3 10-15  24 17.39 
4 15-20  24 22.02 4 15-20  14 20.29 4 15-20  29 21.01 
5 20-25  13 11.93 5 20-25  13 18.84 5 20-25  26 18.84 
6 25-30  9 8.26 6 25-30  13 18.84 6 25-30  17 12.32 
7 30-35  5 4.59 7 30-35  2 2.9 7 30-35  9 6.52 
8 35-40  5 4.59 8 35-40  4 5.8 8 35-40  5 3.62 
9 40-45  2 1.83 9 40-45  1 1.45 9 40-45  3 2.17 
10 45-50  1 0.92 10 45-50  0 0 10 45-50  1 0.72 
               TOTAL       
           
      Bin 
   
Lengt
h 
    
Count 
    
Count 
           
               (µm)              (%) 
           1 0-5 12 3.80 
           2 5-10 48 15.19 
           3 10-15 60 18.99 
           4 15-20 67 21.20 
           5 20-25 52 16.46 
           6 25-30 39 12.34 
           7 30-35 16 5.06 
           8 35-40 14 4.43 
           9 40-45 6 1.90 
           10 45-50 2 0.63 
           
  
Total 
Coun
t 
316   
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Eutajet 
      
Bin    Length 
 
    
Count 
    
Count 
      
Bin 
   
Length 
 
    
Count 
    
Count 
      
Bin 
   
Length 
 
    
Count 
    
Count 
               (µm) 
 
             (%)           
     
(µm) 
 
             (%)           
     
(µm) 
 
             (%) 
1 0-5  22 8.98 1 0-5  5 2.36 1 0-5  0 0 
2 5-10  27 11.02 2 5-10  66 31.13 2 5-10  38 12.03 
3 10-15  43 17.55 3 10-15  44 20.75 3 10-15  107 33.86 
4 15-20  57 23.27 4 15-20  51 24.06 4 15-20  89 28.16 
5 20-25  48 19.59 5 20-25  26 12.26 5 20-25  63 19.94 
6 25-30  29 11.84 6 25-30  10 4.72 6 25-30  15 4.75 
7 30-35  9 3.67 7 30-35  4 1.89 7 30-35  4 1.27 
8 35-40  7 2.86 8 35-40  2 0.94 8 35-40  0 0 
9 40-45  1 0.41 9 40-45  3 1.42 9 40-45  0 0 
10 45-50  2 0.82 10 45-50  1 0.47 10 45-50  0 0 
               TOTA
L 
                    
Bin    Length 
   
Count 
   
Count 
           
               (µm)              (%) 
           
1 0-5 27 3.49 
           
2 5-10 131 16.95 
           
3 10-15 194 25.10 
           
4 15-20 197 25.49 
           
5 20-25 137 17.72 
           
6 25-30 54 6.99 
           
7 30-35 17 2.20 
           
8 35-40 9 1.16 
           
9 40-45 4 0.52 
           
10 45-50 3 0.39 
           
 
Total 
Count 773 
             
 
 
 
 
 
Q-cell 
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Bin    Length 
 
    
Count 
    
Count 
      
Bin 
   
Length 
 
    
Count 
    
Count 
      
Bin 
   
Length 
 
    
Count 
    
Count 
               (µm) 
 
             (%)           
     
(µm) 
 
             (%)           
     
(µm) 
 
             (%) 
1 0-5  1 1.27 1 0-5  8 8.51 1 0-5  1 63.54 
2 5-10  4 5.06 2 5-10  16 17.02 2 5-10  9 9.38 
3 10-15  15 18.99 3 10-15  30 31.91 3 10-15  11 11.46 
4 15-20  18 22.78 4 15-20  20 21.28 4 15-20  2 2.08 
5 20-25  18 22.78 5 20-25  11 11.7 5 20-25  3 3.13 
6 25-30  16 20.25 6 25-30  5 5.32 6 25-30  2 2.08 
7 30-35  5 6.33 7 30-35  3 3.19 7 30-35  2 2.08 
8 35-40  2 2.53 8 35-40  1 1.06 8 35-40  3 3.13 
9 40-45  0 0 9 40-45  0 0 9 40-45  2 2.08 
10 45-50  0 0 10 45-50  0 0 10 45-50  1 1.04 
               TOTA
L 
                    
Bin    Length 
   
Count 
   
Count 
           
               (µm)              (%) 
           
1 0-5 10 4.78 
           
2 5-10 29 13.88 
           
3 10-15 56 26.79 
           
4 15-20 40 19.14 
           
5 20-25 32 15.31 
           
6 25-30 23 11.00 
           
7 30-35 10 4.78 
           
8 35-40 6 2.87 
           
9 40-45 2 0.96 
           
10 45-50 1 0.48 
           
 
Total 
Count 209 
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11.2.2 Chapter 5 Microsphere Attachment Studies Results 
Oven Temperature Characterisation Study Results 
Time (min) Time (s) 1 2 3 4 5 Average STD 
0 0 20 22 23 22 23 22 1.224745 
0.17 10 25 28 27 28 28 27.2 1.30384 
0.33 20 27 30 30 31 32 30 1.870829 
0.5 30 29 32 32 34 36 32.6 2.607681 
0.67 40 31 34 34 36 38 34.6 2.607681 
0.83 50 33 36 36 38 40 36.6 2.607681 
1 60 35 37 38 40 43 38.6 3.04959 
1.17 70 37 39 40 41 46 40.6 3.361547 
1.33 80 39 40 41 44 49 42.6 4.037326 
1.5 90 41 41 43 46 51 44.4 4.219005 
1.67 100 42 42 44 49 54 46.2 5.215362 
1.83 110 43 44 45 50 55 47.4 5.029911 
2 120 44 46 47 52 57 49.2 5.263079 
2.17 130 45 47 49 53 58 50.4 5.176872 
2.33 140 46 48 50 54 59 51.4 5.176872 
2.5 150 48 50 51 55 59 52.6 4.393177 
2.67 160 49 51 53 56 60 53.8 4.32435 
2.83 170 50 51 54 56 60 54.2 4.024922 
3 180 51 52 55 56 61 55 3.937004 
3.17 190 53 53 55 57 61 55.8 3.34664 
3.33 200 53 54 56 57 62 56.4 3.507136 
3.5 210 54 55 57 57 63 57.2 3.49285 
3.67 220 54 57 57 57 65 58 4.123106 
3.83 230 55 58 57 57 65 58.4 3.847077 
4 240 55 59 58 58 66 59.2 4.086563 
4.17 250 55 59 58 59 66 59.4 4.037326 
4.33 260 56 60 58 60 67 60.2 4.147288 
4.5 270 56 60 58 61 67 60.4 4.159327 
4.67 280 56 61 58 62 67 60.8 4.207137 
4.83 290 56 61 58 63 67 61 4.301163 
5 300 56 61 58 63 67 61 4.301163 
5.17 310 56 61 58 63 67 61 4.301163 
5.33 320 56 61 58 63 66 60.8 3.962323 
5.5 330 56 61 58 63 66 60.8 3.962323 
5.67 340 55 61 58 63 66 60.6 4.27785 
5.83 350 55 61 59 63 66 60.8 4.147288 
6 360 55 60 59 63 65 60.4 3.847077 
119 
 
6.17 370 55 60 60 63 65 60.6 3.781534 
6.33 380 54 60 60 62 65 60.2 4.024922 
6.5 390 54 60 61 62 64 60.2 3.768289 
6.67 400 54 59 61 62 64 60 3.807887 
6.83 410 54 59 61 61 63 59.6 3.435113 
7 420 54 59 61 61 63 59.6 3.435113 
7.17 430 54 58 61 62 63 59.6 3.646917 
7.33 440 54 58 61 63 62 59.6 3.646917 
7.5 450 55 58 61 63 62 59.8 3.271085 
7.67 460 55 57 61 64 61 59.6 3.577709 
7.83 470 56 57 61 64 61 59.8 3.271085 
8 480 56 57 61 65 60 59.8 3.563706 
8.17 490 56 58 61 65 60 60 3.391165 
8.33 500 56 58 61 64 60 59.8 3.03315 
8.5 510 56 59 61 64 61 60.2 2.949576 
8.67 520 56 59 61 64 62 60.4 3.04959 
8.83 530 56 59 62 64 63 60.8 3.271085 
9 540 56 59 62 64 63 60.8 3.271085 
9.17 550 56 59 63 65 63 61.2 3.63318 
9.33 560 56 59 63 66 63 61.4 3.911521 
9.5 570 56 59 63 67 63 61.6 4.219005 
9.67 580 56 59 63 67 63 61.6 4.219005 
9.83 590 56 59 63 67 63 61.6 4.219005 
10 600 57 59 63 67 64 62 4 
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Microsphere Attachment Studies Results 
A1 A2 A3 
 Field #        Count  Field # 
       
Count  Field # 
       
Count 
1 150 1 60 1 50 
2 50 2 20 2 70 
3 30 3 20 3 10 
      
Total        230 Total        100 Total        130 
Mean         76.67 Mean         33.33 Mean         43.33 
Std Dev      52.49 Std Dev      18.86 Std Dev      24.94 
Std 
Error    30.31 
Std 
Error    10.89 
Std 
Error    14.4 
W1 W2 W3 
 Field #        Count  Field # 
       
Count  Field # 
       
Count 
1 230 1 40 1 130 
2 310 2 40 2 60 
3 220 3 80 3 110 
      
Total        760 Total        160 Total        300 
Mean         253.33 Mean         53.33 Mean         100 
Std Dev      40.28 Std Dev      18.88 Std Dev      29.44 
Std 
Error    23.25 
Std 
Error    10.89 
Std 
Error    17 
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11.2.3 Chapter 6 Drug Release Studies Results 
 
 
Chloramphenicol Calibration Data 
Calibration curve 
     Concentration 
(µg/mL) Absorbance ε 
    
100 2.914 0.02914 
 
Calibration Co-
efficient  0.0297 µg/ml 
50 1.546 0.03092 
    25 0.805 0.0322 
    12.5 0.419 0.03352 
    6.25 0.225 0.036 
    3.125 0.125 0.04 
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Images 
  
  
 
From top left to bottom right: chemically etched microspheres on scaffold, CAP infused scaffolds, 
Intact microspheres on scaffolds, Negative control, and Positive control. 
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Mass of Drug Vector 
  Initial Mass (g) After Loading (g) Mass Difference (g) Mass Difference (mg) Effective Mass of Drug Vector (mg) 
Positive control 1 0.02358 0.02303 -0.00055 -0.55 23.03 
Positive control 2 0.02353 0.0227 -0.00083 -0.83 22.7 
Positive control 3 0.02385 0.0232 -0.00065 -0.65 23.2 
Intact Microspheres 1 0.02467 0.0252 0.00053 0.53 0.53 
Intact Microspheres 2 0.02362 0.02524 0.00162 1.62 1.62 
Intact Microspheres 3 0.02476 0.0256 0.00084 0.84 0.84 
Chemical  Etched Microspheres 1 0.02328 0.02624 0.00296 2.96 2.96 
Chemical  Etched Microspheres 2 0.02368 0.0258 0.00212 2.12 2.12 
Chemical  Etched Microspheres 3 0.0242 0.02495 0.00075 0.75 0.75 
Negative Control 1 0.03219 0.03228 9E-05 0.09 32.28 
Negative Control 2 0.02251 0.02254 3E-05 0.03 22.54 
Negative Control 3 0.02729 0.02732 3E-05 0.03 27.32 
Infused Scaffolds 1 0.03656 0.03476 -0.0018 -1.8 34.76 
Infused Scaffolds 2 0.0478 0.03994 -0.00786 -7.86 39.94 
Infused Scaffolds 3 0.0396 0.0281 -0.0115 -11.5 28.1 
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Raw Absorption Data 
Time (days) 0 0.006944 0.020833 0.041667 0.083333 0.125 0.166667 1 3 7 
Time (minutes) 0 10 30 60 120 180 240 1440 4320 10080 
Positive control 1 0 0.119 0.174 0.257 0.321 0.33 0.336 0.492 0.474 0.474 
Positive control 2 0 0.135 0.189 0.25 0.303 0.299 0.298 0.422 0.43 0.429 
Positive control 3 0 0.12 0.206 0.273 0.348 0.332 0.358 0.468 0.484 0.495 
Average 0 0.124667 0.189667 0.26 0.324 0.320333 0.330667 0.460667 0.462667 0.466 
Intact Microspheres 1 0 0.075 0.105 0.128 0.139 0.138 0.136 0.136 0.135 0.134 
Intact Microspheres 2 0 0.232 0.288 0.35 0.37 0.375 0.378 0.387 0.392 0.392 
Intact Microspheres 3 0 0.149 0.208 0.223 0.248 0.25 0.257 0.253 0.263 0.26 
Average 0 0.152 0.200333 0.233667 0.252333 0.254333 0.257 0.258667 0.263333 0.262 
Chemical  Etched Microspheres 1 0 0.178 0.222 0.213 0.243 0.245 0.251 0.255 0.25 0.274 
Chemical  Etched Microspheres 2 0 0.18 0.203 0.217 0.237 0.239 0.24 0.248 0.252 0.262 
Chemical  Etched Microspheres 3 0 0.065 0.079 0.078 0.077 0.07 0.074 0.072 0.073 0.076 
Average 0 0.141 0.168 0.169333 0.185667 0.184667 0.188333 0.191667 0.191667 0.204 
Negative Control 1 0 0.018 0.017 0.01 0.017 -0.033 -0.032 0.004 0.008 0.015 
Negative Control 2 0 0.005 0.003 0.005 0.006 0.011 0.005 -0.01 0.001 0.01 
Negative Control 3 0 0.011 0.009 0.0012 0.01 0.002 -0.002 0.01 0.004 0.015 
Average 0 0.011333 0.009667 0.0054 0.011 -0.00667 -0.00967 0.001333 0.004333 0.013333 
Infused Scaffolds 1 0 0.033 0.106 0.198 0.284 0.286 0.324 0.504 0.519 0.51 
Infused Scaffolds 2 0 0.053 0.23 0.23 0.293 0.293 0.345 0.507 0.527 0.526 
Infused Scaffolds 3 0 0.06 0.174 0.174 0.228 0.23 0.237 0.356 0.366 0.366 
Average 0 0.048667 0.17 0.200667 0.268333 0.269667 0.302 0.455667 0.470667 0.467333 
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Calibrated Data (µg) 0 0.006944 0.020833 0.041667 0.083333 0.125 0.166667 1 3 7 
A/e*V +previous m/ml*0.1 0 10 30 60 120 180 240 1440 4320 10080 
Positive control 1 0 20.03367 29.10774 42.12939 51.67568 52.21059 52.0441 74.04542 70.30911 68.6654 
Positive control 2 0 22.72727 31.63636 41.04968 48.8047 47.34816 46.18082 63.54476 63.70009 62.14806 
Positive control 3 0 20.20202 34.39057 44.82306 56.00452 52.61246 55.38617 70.56414 71.6778 71.66693 
Average 0 20.98765 31.71156 42.66738 52.16163 50.72374 51.2037 69.38477 68.56234 67.49346 
Standard Deviation 0 1.508903 2.642217 1.943366 3.624428 2.930233 4.659863 5.348754 4.266075 4.866442 
Intact Microspheres 1 0 12.62626 17.57576 21.04556 22.43508 21.85108 21.08108 20.61662 20.01401 19.41494 
Intact Microspheres 2 0 39.05724 48.2963 57.5513 59.75117 59.35211 58.56299 58.63473 58.08682 56.7852 
Intact Microspheres 3 0 25.08418 34.81818 36.75098 40.01144 39.57185 39.79965 38.36592 38.94939 37.67348 
Average 0 25.58923 33.56341 38.44928 40.73256 40.25835 39.81458 39.20576 39.01674 37.95787 
Standard Deviation 0 13.22272 15.39866 18.31203 18.66849 18.75994 18.74096 19.02297 19.03649 18.68675 
Chemical  Etched Microspheres 1 0 29.96633 37.22559 35.18395 39.18754 38.77991 38.87334 38.64163 37.07351 39.60965 
Chemical  Etched Microspheres 2 0 30.30303 34.09764 35.76658 38.25019 37.83067 37.18604 37.5671 37.33865 37.91885 
Chemical  Etched Microspheres 3 0 10.94276 13.25253 12.87652 12.45345 11.10672 11.45357 10.92119 10.81723 10.99904 
Average 0 23.73737 28.19192 27.94235 29.96373 29.2391 29.17099 29.04331 28.40979 29.50918 
Standard Deviation 0 11.08174 13.03208 13.05064 15.17159 15.71027 15.36691 15.70341 15.23618 16.05253 
Negative Control 1 0 3.030303 2.86532 1.674638 2.725124 -5.05313 -4.95834 0.482407 1.169213 2.148403 
Negative Control 2 0 0.841751 0.511785 0.818525 0.966548 1.724269 0.79506 -1.46381 0.111513 1.416735 
Negative Control 3 0 1.851852 1.521886 0.224998 1.587179 0.343534 -0.29556 1.474913 0.612645 2.13546 
Average 0 1.907969 1.632997 0.906054 1.759617 -0.99511 -1.48628 0.164502 0.631124 1.900199 
Standard Deviation 0 1.095355 1.180695 0.728773 0.891879 3.581516 3.055936 1.494934 0.529092 0.418743 
Infused Scaffolds 1 0 5.555556 17.59933 32.35917 45.61691 45.26687 50.07497 75.77944 76.86367 73.90874 
Infused Scaffolds 2 0 8.922559 38.12458 37.94977 47.15762 46.38383 53.28107 76.29513 78.03364 76.19857 
Infused Scaffolds 3 0 10.10101 28.90909 28.71119 36.67896 36.4033 36.70047 53.55631 54.20709 53.01821 
Average 0 8.193042 28.211 33.00671 43.15116 42.68466 46.6855 68.54363 69.70147 67.70851 
Standard Deviation 0 2.358906 10.28042 4.653204 5.657786 5.468415 8.794628 12.98196 13.43127 12.77359 
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Calibrated Data (µg/mg) 0 0.006944 0.020833 0.041667 0.083333 0.125 0.166667 1 3 7 
 
0 10 30 60 120 180 240 1440 4320 10080 
Positive control 1 0 0.869894 1.263906 1.829326 2.243842 2.267069 2.25984 3.215173 3.052936 2.981563 
Positive control 2 0 1.001201 1.393672 1.808356 2.149987 2.085822 2.034397 2.799329 2.806171 2.7378 
Positive control 3 0 0.870777 1.482352 1.932028 2.413988 2.267778 2.387335 3.041558 3.089561 3.089092 
Average 0 0.913958 1.379977 1.85657 2.269272 2.20689 2.227191 3.018686 2.982889 2.936152 
Standard Deviation 0 0.075557 0.109865 0.066185 0.133825 0.104848 0.17872 0.208863 0.154134 0.179995 
Intact Microspheres 1 0 23.82314 33.16181 39.7086 42.33034 41.22845 39.77563 38.89928 37.76229 36.63196 
Intact Microspheres 2 0 24.10941 29.81253 35.52549 36.88344 36.6371 36.14999 36.19428 35.85606 35.05259 
Intact Microspheres 3 0 29.86211 41.45022 43.75117 47.63266 47.10934 47.38054 45.67371 46.36833 44.84938 
Average 0 25.93155 34.80818 39.66175 42.28215 41.6583 41.10205 40.25576 39.99556 38.84464 
Standard Deviation 0 3.406974 5.990982 4.113037 5.374773 5.249334 5.731564 4.883128 5.600674 5.25987 
Chemical  Etched Microspheres 1 0 10.12376 12.57621 11.88647 13.23904 13.10132 13.13289 13.0546 12.52483 13.38164 
Chemical  Etched Microspheres 2 0 14.29388 16.08379 16.87103 18.04254 17.84466 17.54059 17.72033 17.61257 17.88625 
Chemical  Etched Microspheres 3 0 14.59035 17.67003 17.16869 16.60459 14.80896 15.27143 14.56159 14.42298 14.66538 
Average 0 13.00266 15.44335 15.30873 15.96206 15.25164 15.31497 15.11217 14.85346 15.31109 
Standard Deviation 0 2.497606 2.606604 2.9675 2.465372 2.402454 2.204172 2.381093 2.571041 2.320685 
Negative Control 1 0 0.093876 0.088765 0.051878 0.084421 -0.15654 -0.1536 0.014944 0.036221 0.066555 
Negative Control 2 0 0.037345 0.022706 0.036314 0.042881 0.076498 0.035273 -0.06494 0.004947 0.062854 
Negative Control 3 0 0.067784 0.055706 0.008236 0.058096 0.012574 -0.01082 0.053987 0.022425 0.078165 
Average 0 0.066335 0.055725 0.032143 0.0618 -0.02249 -0.04305 0.001329 0.021198 0.069191 
Standard Deviation 0 0.028293 0.033029 0.022118 0.021016 0.120411 0.098477 0.060622 0.015673 0.007988 
Infused Scaffolds 1 0 0.159826 0.50631 0.930931 1.312339 1.302269 1.440592 2.180076 2.211268 2.126258 
Infused Scaffolds 2 0 0.223399 0.954546 0.950169 1.180712 1.161338 1.334028 1.910244 1.953772 1.907826 
Infused Scaffolds 3 0 0.359467 1.028793 1.021751 1.305301 1.295491 1.306066 1.905918 1.929078 1.886769 
Average 0 0.247564 0.829883 0.967617 1.266117 1.253033 1.360229 1.998746 2.031373 1.973618 
Standard Deviation 0 0.10199 0.282671 0.047858 0.074047 0.079482 0.070987 0.157051 0.156283 0.132609 
 
